[
    {
        "utterance": "Dr. Anna Moore: Sandin at the College of Human Medicine. Uh prior to joining MSU, which was about three years ago, uh my career all my career pretty much went at Massachusetts General Hospital and Harvard Medical School that I joined as postdoctoral fellow and by the time I left I was a professor at Harvard Medical School, professor in radiology. So, uh my personal interest in science is image guided therapy for metastatic cancers. ",
        "annotations": {
            "explain or define term or concept": "The speaker is defining her background and research interests, which is a concept relevant to the discussion."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um, in the beginning of my career, I used uh iron oxide nanoparticles as contrast agents uh to detect tumors and now we're using them actually as uh carriers as vehicles to deliver therapies and as imaging reporters as well, that's why it's image guided therapy. ",
        "annotations": {
            "explain or define term or concept": "The speaker explains the concept of image-guided therapy by describing how iron oxide nanoparticles are used as carriers and imaging reporters, clarifying the term for the audience."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So that's it. Um, I mean, I can take tell you more, but I think we should try to keep it short. ",
        "annotations": {
            "propose decision": "Dr. Moore suggests keeping the introduction brief, proposing a decision on the level of detail to provide."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, um, I I'm just going to go the way I see people on the screen, so no or or no, I do have a list here. Okay, let's just go alphabetically. Benjamin. ",
        "annotations": [
            {
                "propose decision": "Dr. Anna Moore proposes a method for choosing who speaks next by stating she will go by the order of people on her screen or alphabetically by a list she has."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: Hi. Uh, I'm Ben Benjamin Bartel. I'm assistant professor just started this year at Arizona State University. I work on uh molecular tools for MRI. My goal is to uh non-invasively resolve and manipulate the neuroimmune system. So I do that with a combination of um uh just direct MRI methods uh through um just image analysis and I also build a host of molecular tools using directed evolution, signaling reporters, direct molecular sensors, etc. all for MRI and all in vivo. ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker explains his work on molecular tools for MRI, clarifying his research focus for the team."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: We met yesterday, right? ",
        "annotations": {
            "ask clarifying question": "Dr. Moore is asking for confirmation about whether she and Benjamin met the previous day, seeking to clarify their prior interaction."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah, I think we did. ",
        "annotations": {
            "express agreement": "Benjamin explicitly agrees with Anna's question about whether they met yesterday."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, they screwed up a little bit the facilitators and the group, so I was supposed to be in the other group at the beginning. So, but that's fine. So it's all good to see faces that you've seen before. ",
        "annotations": [
            {
                "express humor": "Dr. Anna Moore makes a lighthearted comment about a mix-up with the facilitators and groups, using the phrase \"screwed up a little bit\" in a somewhat humorous way."
            },
            {
                "acknowledge contribution": "Dr. Anna Moore acknowledges that she has seen some of the faces before, which is a way of recognizing their prior presence and participation."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: All right. Uh Molly. ",
        "annotations": {
            "encourage particpatioin": "Dr. Anna Moore is inviting Molly to introduce herself and contribute to the discussion, continuing the round of introductions."
        }
    },
    {
        "utterance": "Molly Bright: Hi, I'm Molly Bright. I'm at Northwestern in Chicago. Uh, I also do in vivo work with MRI, but with humans. Um, I mostly look at quantifying aspects of the plumbing. So blood flow supplied to the tissue, how that blood flow is regulated or misregulated, um, aspects of oxygen delivery and metabolism. Uh, but I also like to think about how all of that vascular infrastructure supports or doesn't support healthy neural function. So, um, I do a lot of work now in in patients thinking about rehabilitation. So what can we do after something's happened to try to recover and repair both the neural and vascular systems. ",
        "annotations": [
            {
                "explain or define term or concept": "Molly explains her research focus, which involves quantifying aspects of blood flow, regulation, oxygen delivery, and metabolism in relation to neural function, clarifying her area of expertise."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Wonderful. Dylan. ",
        "annotations": {
            "express enthusiasm": "Dr. Anna Moore says \"Wonderful\", expressing enthusiasm about the introductions.",
            "encourage particpatioin": "Dr. Anna Moore says \"Dylan\", inviting Dylan to introduce himself."
        }
    },
    {
        "utterance": "Dylan Burnette: Hi, I'm Dylan Burnette. Um, I am an associate professor at Vanderbilt University. I just am just barely on the other side of tenure now. Uh although I still feel like I have like new people problems. Um, but I am a cell biologist by training and so I've been using light microscopes for about 20 years or so, a little bit more unfortunately. Um as I'm getting older. Uh to to study uh the cell skeleton. And so my my lab we kind of took that interest in in the cell skeleton to ask a very simple question. How does a heart grow on a single cell level? Meaning how does a single heart muscle cell physically get bigger? And that is one of the main drivers of our lab. Uh and we do attack that in multiple ways and it occurred to us a few years ago, actually about a year ago now that we could use the same technologies we're using to start mimicking what's happening inside of patients in in a in a uh basically a dish. And so we are now developing uh systems to mimic ischemia and reperfusion injury in our cardiac myos and that's allowed us to start doing screening and I have no idea what I'm doing and it's phenomenal. I have we're having a very good time. Uh and so we are kind of all over the place. We're we're looking at individual sarcomeres and we're looking to find some drugs. ",
        "annotations": [
            {
                "explain or define term or concept": "Dylan explains his background as a cell biologist using light microscopes to study the cell skeleton, providing context for his later research."
            },
            {
                "present new idea": "Dylan introduces the idea of mimicking what's happening inside patients in a dish to study heart growth at a single-cell level, which is a novel approach for his lab."
            },
            {
                "express enthusiasm": "Dylan expresses enthusiasm about his lab's work, stating that they are having a very good time and that it's phenomenal."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Okay. All right, sounds good. Morteza. ",
        "annotations": {
            "encourage particpatioin": "Dr. Anna Moore is moving through the list of participants and inviting Morteza to introduce himself."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Hi, my name is Morteza Mahmoudi and uh I'm an assistant professor at Michigan State University. My work is uh focused on nanomedicine and regenerative medicine and basically we use imaging technique to basically probe nanoparticles. if we use them for like therapeutic approaches like MRI approaches, if we use like magnetic based nanoparticles. Uh, but uh most importantly we try to understand what happens at the surface of nanoparticles. So for that purpose we combine cryo transmission electron microscopy and uh 3D constructed imaging model to basically see the 3D structure of the nanoparticles and how they interact with proteins and at the larger scale how they interact with different cell types and what are their uh trafficking inside the cells. ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker is explaining their research focus, which involves nanomedicine, regenerative medicine, and the use of imaging techniques to study nanoparticles, providing context for their expertise."
            }
        ]
    },
    {
        "utterance": "Morteza Mahmoudi: Paris. ",
        "annotations": {
            "None": "This utterance is simply stating the name 'Paris' and does not fit any of the codes in the codebook."
        }
    },
    {
        "utterance": "Paris Perdikaris: Hello everyone. So my name is Paris Perdicarris and I'm assistant professor at the Department of Mechanical Engineering at the University of Pennsylvania. Um, my background actually is in applied mathematics and my work is focused on developing machine learning methods and computational tools for modeling and simulation of physical and biological systems. I think most relevant to this meeting in some is some work I'm pursuing on physics based filtering of um uh in vivo MRI uh with a focus on 4D flow MRI and reconstructing blood flow and measurements in a way that the underlying physics is satisfied, so principles like mass and momentum conservation and then using those principles to infer auxiliary measurements that um cannot be measured by imaging such as blood pressure, uh shear stresses, um uh and so forth. So the idea there is really to understand the role of hemodynamics in determining organ function and uh you know, predicting biomarkers that are relevant to cardiovascular disease. ",
        "annotations": [
            {
                "explain or define term or concept": "Paris explains his work focuses on developing machine learning methods and computational tools for modeling and simulation of physical and biological systems, which clarifies his area of expertise."
            },
            {
                "present new idea": "Paris introduces his work on physics-based filtering of in vivo MRI, focusing on 4D flow MRI and reconstructing blood flow measurements, which is a novel concept not previously discussed in the introductions."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Wonderful, Lisa. ",
        "annotations": {
            "encourage particpatioin": "Dr. Anna Moore is moving through the list of participants and inviting each to introduce themselves, so she is encouraging Lisa to participate."
        }
    },
    {
        "utterance": "Lisa Poulikakos: Hi everyone, I'm Lisa Poulikakos. I'm an assistant professor at UC San Diego. My research works on nanophotonics, so the study and manipulation of light at the nanoscale. Um, and some questions I'm really interested in is how can we scale down the complex manipulation of light. So a lot of these really sophisticated imaging techniques using state of the art nano optics can actually be realized on a single optical surface, which is then uh nano patterned in intricate ways and then can really be easily deployed in a variety of in vivo and ex vivo applications. Um and some questions that I find interesting um recently are how can we uh enhance polarized light matter interactions to learn more about the structural properties of molecules or tissues, for example. ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker defines nanophotonics as the study and manipulation of light at the nanoscale, providing context for their research."
            },
            {
                "present new idea": "The speaker introduces the idea of scaling down complex light manipulation onto a single optical surface for in vivo and ex vivo applications, which is a novel concept in the context of the discussion."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Okay, thank you. Crystal. ",
        "annotations": {
            "acknowledge contribution": "Dr. Anna Moore acknowledges the previous speaker's contribution with 'thank you' before moving on to the next person."
        }
    },
    {
        "utterance": "Crystal Rogers: Hi everyone. Uh my name is Crystal Rogers and I am an assistant professor at UC Davis. I am a developmental uh molecular and cell biologist and my research focuses on on understanding um the roles of transcription factors and cell cell adhesion molecules in regulating the process of the epithelial to transition. So I study neural crest cells um and those cells are really dynamic and they make a lot of different um adult tissues, but probably more relevant to this group, uh all of the molecular mechanisms that allow those cells to undergo EMT are then re uh reused by cancer cells to metastasize. And so what we are doing in my lab is really trying to get at the basal function of the proteins that allow these cells to undergo EMT and to migrate and differentiate and then um at least my postdoc is really interested in trying to define whether those functions um are conserved in disease states. And so we do a lot of fixed and live imaging of these cells to get at um how the collective migration works um and and the paths that these cells take and then um hopefully how that's affected by perturbations of these different proteins. ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker explains their research focus on transcription factors and cell-cell adhesion molecules in regulating epithelial-mesenchymal transition (EMT), providing context for their work."
            },
            {
                "provide supporting evidence": "The speaker supports the relevance of their work to the group by mentioning that the molecular mechanisms of EMT are reused by cancer cells to metastasize, linking their basic research to a disease context."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Very, very interesting. ",
        "annotations": {
            "acknowledge contribution": "Dr. Moore acknowledges Crystal Rogers's contribution after Crystal described her research on neural crest cells and their relevance to cancer metastasis."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Right in line with what we're doing too, so okay. Uh Mark. ",
        "annotations": {
            "acknowledge contribution": "Dr. Moore acknowledges Crystal Rogers' introduction of her research, noting its relevance to their work.",
            "encourage particpatioin": "Dr. Moore prompts Mark to introduce himself and his work to the group."
        }
    },
    {
        "utterance": "mark sellmyer: that we can't do at this point. And another the other component is really around imaging gene and cell therapies and if we can image it and control it then perhaps we can get into that, you know, positive feedback loop of modulating something in the therapy and then seeing how that changes. So, um, thanks. ",
        "annotations": {
            "reject idea": "The phrase \"that we can't do at this point\" indicates a dismissal of a previously mentioned idea.",
            "present new idea": "The speaker introduces the idea of imaging gene and cell therapies to control and modulate them, which is a novel concept in the context of the discussion.",
            "expand on existing idea": "The speaker builds on the idea of imaging gene and cell therapies by adding the detail that if we can image and control it, we can get into a positive feedback loop of modulating the therapy and seeing how that changes."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh I just don't want to mispronounce your name. Sixian, Sixian, is that the right way to say it? ",
        "annotations": {
            "acknowledge contribution": "Dr. Moore acknowledges Mark's contribution by saying 'Okay' after he finishes speaking.",
            "ask clarifying question": "Dr. Moore asks Sixian if she is pronouncing their name correctly to ensure she is addressing them properly."
        }
    },
    {
        "utterance": "Sixian You: Uh, yeah, close enough. So my name is uh Sixian You. Yes. Uh, so I'm assistant professor in electrical engineering at MIT. I just started uh this March. Uh, I did my PhD in UIUC uh in label free microscopy. And then I did my uh postdoc in Berkeley in computational imaging. So my new lab uh the goal is to see how to use optics and algorithms to enable breakthroughs in biomedicine, especially the clinical adoption of microscopy in different uh biomedical situations like early cancer diagnosis, image guided therapies and neuroimaging. So I'm very interesting this session uh the reason I've never done anything like image guided therapies before, but uh I'm very curious how can I contribute? How can I use label free imaging, how can I use optics and algorithms to enable point of procedure diagnosis uh or point of procedure real time monitoring of the therapeutic process. Uh, what role would a resolution of cellular dynamics mean in the in the process of imaging guided therapies. ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker is introducing themself and their background, which includes defining their area of expertise as label free microscopy and computational imaging."
            },
            {
                "present new idea": "The speaker is presenting the goal of their new lab, which is to use optics and algorithms to enable breakthroughs in biomedicine, especially the clinical adoption of microscopy in different biomedical situations."
            },
            {
                "encourage particpatioin": "The speaker is expressing curiosity about how they can contribute to image-guided therapies, inviting ideas on how their expertise in label-free imaging, optics, and algorithms can be applied."
            },
            {
                "ask clarifying question": "The speaker is asking about the role of cellular dynamics resolution in image-guided therapies, seeking to understand its importance in the process."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Thank you so much. And then there's other people who are not on my list. I don't know if you guys want to introduce yourself. Um. ",
        "annotations": {
            "acknowledge contribution": "Dr. Anna Moore thanks the previous speaker for their introduction.",
            "encourage particpatioin": "Dr. Anna Moore invites others who are not on her list to introduce themselves."
        }
    },
    {
        "utterance": "Arne Bakker (he/him) | CZI: So I'll just briefly say hi if that's okay just to you know who I am. I'm Arne Bakker, I'm at CZI, I'm the director of meetings and community um and so me and my team we host meetings like this about 15 to 20 times a year for the the the the scientists that CZI funds to really uh hope to encourage collaboration and sharing of knowledge. Um and I have a PhD in immunology and did my postdoc at Berkeley and my PhD at the Netherlands Cancer Institute in Amsterdam uh hence my interest in this topic. Uh but I'm mostly here to observe so I'm going to probably throw my camera off and and listen in but uh looking forward to hearing the conversation. ",
        "annotations": [
            {
                "explain or define term or concept": "Arne is introducing himself and his role at CZI, explaining that he is the director of meetings and community, which clarifies his presence and purpose at the meeting."
            },
            {
                "encourage particpatioin": "Arne is introducing himself and then stating he will observe, which encourages the other participants to continue with their introductions and discussions."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh Sandra, do you want to say a couple of words? ",
        "annotations": {
            "encourage particpatioin": "Dr. Anna Moore is inviting Sandra to introduce herself to the group, encouraging her participation in the meeting."
        }
    },
    {
        "utterance": "Sandra Laney - Walder Foundation: Yeah, just really quickly. I'm I'm a guest. I'm from the Walder Foundation based in the Chicago region um and I'm the senior program uh director for science innovation. So really just here as an observer looking forward to hearing the conversation. I also will probably shut my camera off and just participate as a butterfly on the wall. ",
        "annotations": [
            {
                "explain or define term or concept": "Sandra is explaining her role as a guest from the Walder Foundation and her position as the senior program director for science innovation."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Um so um I guess the first thing we need to do is to select a person uh who's going to be recording uh all the great thoughts that hopefully come come out of this meeting. ",
        "annotations": {
            "propose decision": "Dr. Anna Moore suggests the group needs to select a person to record the meeting's ideas, proposing a concrete action for the group to take."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I did it last time, so I'm not going to do it this time, but it was actually very fun. So somebody else should have that opportunity. You're just writing down sketches and then everybody likes you because you did the work. So. ",
        "annotations": [
            {
                "express alternative decision": "Benjamin declines to record notes this time, referencing his prior experience and suggesting someone else take the role."
            },
            {
                "encourage particpatioin": "Benjamin encourages someone else to take on the task of recording notes, framing it as a positive opportunity."
            },
            {
                "express humor": "Benjamin jokes about the benefits of taking notes, implying that it makes others appreciate the note-taker's effort."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: That is very true Ben. So Ben did it the last time yesterday and he did an an amazing job. ",
        "annotations": {
            "acknowledge contribution": "Dr. Anna Moore acknowledges Ben's contribution from the previous meeting, recognizing his effort in recording the notes.",
            "express agreement": "Dr. Anna Moore explicitly agrees with Ben's statement about his previous role and the positive reception he received for it."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Yeah. ",
        "annotations": {
            "express agreement": "Benjamin is agreeing with Dr. Anna Moore's statement that he did an amazing job recording the notes yesterday."
        }
    },
    {
        "utterance": "Dr. Anna Moore: And uh as uh Andrew pointed out, you don't need to fill up that slide uh right away because I guess I guess there's some I don't know, interference or something. My internet is not working very great either. So uh you can just write it down somewhere and then transfer it on the slide. So Ben, do you do you want to just basically give people like a couple of ideas how to do that? So they because they they will look a little bit scared. ",
        "annotations": [
            {
                "assign task": "Dr. Anna Moore asks Ben to provide some guidance on how to record the meeting's key ideas, assigning him the task of explaining the process to others."
            },
            {
                "encourage particpatioin": "Dr. Anna Moore is encouraging Ben to participate by sharing his experience and tips on how to record the meeting's key ideas."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle ASU: Sure. We're um so you know, we all had a conversation yesterday that when people would make a point, they come in and say like, I don't know, we could one thing was we collect more data than we use these days. And so I just wrote that down. Somebody else said, you know, I'm involved in really these large scale projects and we try to collect data for other people. Like, okay, well, put those things together and I just started cluster together the the main points people were making. And they ended up being in about three general categories. And so at the end, I was like, hey everybody, things kind of went into these three categories. That's great. ",
        "annotations": {
            "explain or define term or concept": "Benjamin is explaining how he took notes in the previous meeting, describing his process of clustering main points into general categories.",
            "acknowledge contribution": "Benjamin is acknowledging the contributions of the people in the previous meeting by summarizing the points they made.",
            "encourage particpatioin": "Benjamin is encouraging someone to volunteer to take notes by explaining how he did it in the previous meeting."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh we we we sure did. ",
        "annotations": {
            "express agreement": "Dr. Anna Moore is explicitly agreeing with Benjamin's summary of the previous discussion, indicating that the group did indeed organize the points into three categories."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It's great to be appreciated. I'm just trying to sell it. ",
        "annotations": {
            "express humor": "Benjamin is making a joke about being appreciated for his work as a note-taker, and he is trying to sell the idea of note-taking to others."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Thank you, appreciate that too. All right, so any volunteers? ",
        "annotations": {
            "acknowledge contribution": "Dr. Anna Moore acknowledges Benjamin's contribution to the previous meeting.",
            "encourage particpatioin": "Dr. Anna Moore is encouraging someone to volunteer to take notes."
        }
    },
    {
        "utterance": "Sixian You: That is what. I can do it. I'm a newbie in image guided therapies anyway, so I I'm here to absorb and learn. ",
        "annotations": {
            "assign task": "Sixian volunteers to record the meeting's thoughts, taking on the role that Dr. Anna Moore requested.",
            "express enthusiasm": "Sixian expresses enthusiasm by volunteering to take notes and learn from the discussion.",
            "encourage particpatioin": "Sixian volunteers to take notes, which encourages participation by fulfilling the requested role."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Sixian, thank you so much. That's uh great. So it's actually up to you. You can write, you know, write in the slide if you want. It's up to you or on the, you know, piece of paper on or on the computer screen and then. ",
        "annotations": [
            {
                "acknowledge contribution": "Dr. Anna Moore acknowledges Sixian's willingness to volunteer for note-taking, showing appreciation for their contribution.",
                "assign task": "Dr. Anna Moore assigns the task of recording notes to Sixian, following Sixian's offer to do so.",
                "encourage particpatioin": "Dr. Anna Moore encourages Sixian to participate by giving them the option to write notes on the slide, paper, or computer."
            }
        ]
    },
    {
        "utterance": "Sixian You: Uh, yes. ",
        "annotations": {
            "express agreement": "Sixian You says \"yes\", which expresses agreement with Dr. Anna Moore."
        }
    },
    {
        "utterance": "Dr. Anna Moore: No, no, no, it's slide 42. ",
        "annotations": {
            "explain or define term or concept": "Dr. Anna Moore is clarifying which slide to use, specifying it's slide 42, which is a clarification of a term or concept."
        }
    },
    {
        "utterance": "Sixian You: 42. Okay. ",
        "annotations": [
            {
                "acknowledge contribution": "Sixian acknowledges Dr. Anna Moore's instruction to go to slide 42."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Uh, it's the recovery slide or is the original slide? ",
        "annotations": [
            {
                "ask clarifying question": "Dr. Anna Moore is asking a clarifying question about which slide to use, either the recovery slide or the original slide."
            }
        ]
    },
    {
        "utterance": "Molly Bright, Northwestern: Whichever one is for our room. It doesn't matter what number slide it is. If it's the one for 2.3. ",
        "annotations": [
            {
                "explain or define term or concept": "Molly is clarifying which slide Sixian should use for recording notes, specifying that it should be the one designated for their breakout room, regardless of the slide number."
            }
        ]
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So we're saying there's versions of the document and we should use the one that doesn't say recovery somehow just so if I understood correctly. ",
        "annotations": [
            {
                "ask clarifying question": "Lisa is asking for confirmation that they should use the document version that doesn't say 'recovery', seeking clarification on which version to use."
            }
        ]
    },
    {
        "utterance": "Molly Bright, Northwestern: Got it. ",
        "annotations": {
            "express agreement": "Molly confirms her understanding of the previous discussion about which version of the document to use."
        }
    },
    {
        "utterance": "Sixian You: That makes sense. Okay. ",
        "annotations": [
            {
                "express agreement": "Sixian You agrees with Molly and Lisa's clarification about using the correct version of the document, indicating understanding and alignment."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I have a slide that doesn't say recovery. Well, okay. ",
        "annotations": [
            {
                "confirm decision": "Dr. Anna Moore confirms that she has the correct slide, which is the one that doesn't say 'recovery', after a discussion about using the correct version of the document."
            }
        ]
    },
    {
        "utterance": "Sixian You: Okay. ",
        "annotations": {
            "acknowledge contribution": "Sixian is acknowledging the information about the slides that was just provided by Molly and Lisa."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: already entered her name. ",
        "annotations": {
            "acknowledge contribution": "Benjamin acknowledges that someone has already entered a name, recognizing their input without necessarily agreeing or expanding on it."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, you can just do that. Okay, great, excellent. ",
        "annotations": [
            {
                "confirm decision": "Dr. Anna Moore confirms that Sixian can write notes on the slide, solidifying the decision for Sixian to be the note taker."
            },
            {
                "express agreement": "Dr. Anna Moore expresses agreement with the suggestion that Sixian can just write notes on the slide."
            },
            {
                "express enthusiasm": "Dr. Anna Moore expresses enthusiasm with the word 'great' and 'excellent' after Sixian agreed to take notes."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: All right, so here we go. Um from models to humans. Um so basically the question is we have uh a lot of uh drugs in the pipeline in in uh petri dishes in the labs uh that were beautifully uh when you seed the cells, you know, and then you sprinkle the drug, cells dead, all good. Uh, totally different issues when you start injecting something in the body, whether it's a mouse, a rat or or human. Well, you can't inject in the human before you inject in the mouse and the rat but anyway, so the big issue is how do you how do you get something somewhere where it needs to go? What are the biological barriers that needs to be overcome? Uh, and the biggest question, I guess, you all know that it takes about 10 years to get something from the bench to to being somewhat approved. Not even fully approved, but somewhat approved. 10 years, uh, tens of millions, sometimes hundred millions of dollars. Just just something has to something has to be done about that. So, um, so we're here to to solve this problem today. ",
        "annotations": [
            {
                "present new idea": "Dr. Anna Moore presents the problem of the lengthy and costly drug approval process, framing it as a challenge the group should address.",
                "explain or define term or concept": "Dr. Anna Moore explains the challenges of translating drug efficacy from in vitro models to in vivo systems, highlighting the biological barriers and complexities involved."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Yes. ",
        "annotations": {
            "express agreement": "Dr. Anna Moore is expressing agreement with a previous statement or idea, likely related to the problem of drug development timelines and costs that she just outlined."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): So as a mechanistic scientist, I just want to to bring up this, you know, start at the base level basically, that the issue or one of the big issues that we have with this is that the con. ",
        "annotations": {
            "present new idea": "Crystal Rogers introduces the idea of starting at the base level to address the issues with translating drugs from the bench to the body, which is a new approach in the conversation."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): of these processes or or you know, pathways, they're not even conserved between people, much less species. And so we have a really uh significant issue if we focus on one model organism and there's no confirmation of of pathways, molecular pathways for treatments. And so as you mentioned, something can be targeted in the mouse and never works in the human and doing research with model organisms, even closely related ones, I can tell you that even within the same order, there's no guarantee that these species have um kind of the same there's not the mechanistic processes aren't the same. So I think we need a lot more basic level research to really define what the conserved pathways that drive these processes of say EMT, cell migration, metastasis are, um before we can jump to treating humans and and we have to have both of those at the same time in my opinion. ",
        "annotations": [
            {
                "provide supporting evidence": "The speaker provides evidence that molecular pathways are not conserved between species, supporting the idea that treatments effective in model organisms may not translate to humans, which is relevant to the discussion about drug development from models to humans.",
                "present new idea": "The speaker presents the idea that more basic level research is needed to define conserved pathways before jumping to treating humans, suggesting a shift in focus towards understanding fundamental mechanisms.",
                "expand on existing idea": "The speaker expands on the existing idea of challenges in translating drug development from models to humans by highlighting the lack of conservation in molecular pathways and mechanistic processes across species."
            }
        ]
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Could I ask a follow up on on Crystal's comment? So I come from the optics and physics side so I'm just learning recently about the biological model making and so on. So how much do some of these relatively recent um 3D physiologically relevant cell culture models help? So so making basically um so so from you know, my reading and talking to some collaborators it seems like people are getting better at making in vitro models of of the human also for drug testing for example. So does that help maybe avoid some animal models or is that completely often brings along a whole other set of challenges? What's kind of the latest um state of the art there? ",
        "annotations": [
            {
                "ask clarifying question": "Lisa asks a question to Crystal, following up on Crystal's comment about the challenges of translating findings from model organisms to humans, and seeks clarification on the utility of 3D cell culture models in bridging this gap."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Are you talking like you know, like spheroid cultures and stuff? ",
        "annotations": {
            "ask clarifying question": "Dr. Anna Moore is asking a clarifying question to Lisa Poulikakos to understand the type of 3D cell culture models she is referring to in the context of drug testing."
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Mainly cell cultures that can reproduce for example also the extracellular environment. So so that are really physiologically relevant but in vitro. ",
        "annotations": {
            "explain or define term or concept": "Lisa is explaining what kind of cell cultures she was referring to in her previous question, specifying that they are cell cultures that reproduce the extracellular environment and are physiologically relevant but in vitro."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It feels very promising, but my personal experiment experience uh recently collaborating with somebody doing a 3D organoid model. Um we got all kinds of interesting data in addition that I went to go validate with some metabolic imaging, just nothing alike. Not even slightly. And so then we just did all the experiments over again and it told a completely different story. It turned out that, you know, sitting in millimolar glucose, which is what you have to do for the cells to survive, completely wrecked their metabolism in terms of you know, what we're looking for. So it is really easy to get to be misled by those tools. I'm not saying they're bad, but it's very easy to get misled because then you think they're real, but something that's required for the culture conditions um ruins everything. And for someone who works in neuroimmunity, like the microglia that I focus on, they know when they're in culture. They know when they're being looked at and they change their their gene transcription. So those things have been have been very frustrating for for my personal kind of work. Now, they may work in other systems, but they they've never worked for me. ",
        "annotations": [
            {
                "provide supporting evidence": "Benjamin shares his personal experience collaborating on a 3D organoid model to support his claim that these models can be misleading, providing specific examples of conflicting data and altered cell behavior in culture."
            },
            {
                "offer constructive criticism": "Benjamin offers constructive criticism by pointing out the potential pitfalls of using 3D organoid models, highlighting how culture conditions can alter cell behavior and lead to misleading results, which is meant to improve the understanding of these models."
            }
        ]
    },
    {
        "utterance": "Sixian You | MIT: I think there are some positive examples for uh breast cancer. So there is a research group in Wisconsin Medicine where they uh have these organoids from patients and they culture it and then they use therapy to uh you know, treat it and then using optical imaging technologies, they are able to see if they decrease or increase. Uh I have not been following up how well that really translates to the patient's recovery because of course that takes long time to track. Uh but maybe the sensitivity. I know neurons are a beast. They are different in every different environment. So maybe some models are more robust in different um scenarios and that's the thing we could take advantage of. ",
        "annotations": [
            {
                "provide supporting evidence": "Sixian provides examples of breast cancer research using organoids and optical imaging to support the idea that 3D cell culture models can be useful, responding to Lisa's question about the utility of 3D cell culture models.",
                "expand on existing idea": "Sixian expands on the discussion of 3D cell culture models by suggesting that some models may be more robust in different scenarios, building on Benjamin's negative experience with organoid models."
            }
        ]
    },
    {
        "utterance": "Dylan Burnette: Yes, I would I would get I would agree with that. Not all organoids are the same. Uh there are some organoids that are much more robust and in vivo like such as the gut organoids are actually making real crips to feed the villi that have the the sites on them. And also the Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": [
            {
                "express agreement": "Dylan agrees with the previous statement that organoids can be useful, building on the discussion about the utility of 3D cell culture models for drug testing.",
                "expand on existing idea": "Dylan expands on the idea that not all organoids are the same by providing an example of gut organoids that are more robust and in vivo-like, adding details to the discussion about the utility of 3D cell culture models."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle ASU: Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "expand on existing idea": "Benjamin is clarifying that his previous comments about organoids were specifically about gut organoids, expanding on the previous discussion about the utility of 3D cell culture models."
        }
    },
    {
        "utterance": "Dylan Burnette: But that was metabolism. Yeah yeah yeah don't don't don't expect them to actually have the right metabolism. That's just that's a big ask. It's surviving and making similar cell types is what we're looking for here. Um that's why I think people we should we should lower our standard a little bit because to expect a something in a dish to be an in vivo environment is never going to happen. In vivo like we can probably get there. In vivo you got to go into an animal for that. ",
        "annotations": [
            {
                "expand on existing idea": "Dylan is expanding on the discussion about organoids and their limitations, specifically in relation to metabolism, which was brought up by Benjamin."
            },
            {
                "offer constructive criticism": "Dylan offers constructive criticism by suggesting to lower the standards for organoids, acknowledging that they cannot perfectly replicate in vivo environments, implying that expecting them to do so is unrealistic."
            }
        ]
    },
    {
        "utterance": "Crystal Rogers (UC Davis): I was going to mention the same paper. Although somebody commented that the mechanism of formation was different in vivo versus in the organoid, but that the function was similar. So I do think there are limitations. ",
        "annotations": {
            "expand on existing idea": "Crystal is building on Sixian's previous statement about a research group in Wisconsin Medicine using organoids for breast cancer treatment, by mentioning the same paper.",
            "provide supporting evidence": "Crystal provides supporting evidence by mentioning a paper that supports the use of organoids, but also acknowledges its limitations by stating that the mechanism of formation was different in vivo versus in the organoid, but that the function was similar."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): But I think multi-disciplinary studies where you have people in vivo and you have organoids and then you are able to, I mean we can't study people, but you can do um patient specific therapeutics, right? So pulling cells or um or tumors out of patients to try to determine in their physiology if they can respond to these things. You kind of have to have all three because with without them you're you're running blind in some areas. ",
        "annotations": {
            "expand on existing idea": "Crystal is expanding on the discussion about the limitations of organoids and in vivo models by suggesting a multi-disciplinary approach that incorporates both, along with patient-specific therapeutics, to overcome the limitations of each individual approach, building on the previous discussion about the pros and cons of different models.",
            "propose decision": "Crystal proposes a multi-disciplinary approach involving in vivo studies, organoids, and patient-specific therapeutics to address the limitations of each individual method, suggesting a concrete choice for the group to consider.",
            "provide supporting evidence": "Crystal supports the idea of using multiple approaches by stating that without all three (in vivo, organoids, and patient-specific therapeutics), research would be incomplete, providing a reason to strengthen the idea."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I think some of us are you can't study people though, right? Uh Molly, you study people, but what you get is not mechanistic per se. It's like a convolution of the mechanisms. And so there's got to be some I I I wish there is some translation between the mechanisms and the convolute the complex outputs of those mechanisms. And a lot of times that's things like blood flow because that's something you can see or biomarkers that are accessible, structural changes, um liquid biopsies, things like that that give you hints as to what the mechanism might be. But um so far uh those things have not been enough to give you a a strong inference of the mechanisms that are so have been so painstakingly acquired in in model systems. ",
        "annotations": {
            "expand on existing idea": "Building on the discussion about the limitations of model organisms and organoids, Benjamin expands on the challenges of studying humans directly, noting that the data obtained is often a complex convolution of mechanisms rather than a clear mechanistic understanding.",
            "acknowledge contribution": "Benjamin acknowledges Molly's work studying people, recognizing her contribution to the discussion.",
            "express frustration": "Benjamin expresses frustration that the complex outputs of mechanisms in human studies have not been enough to give a strong inference of the mechanisms that have been painstakingly acquired in model systems."
        }
    },
    {
        "utterance": "Dylan Burnette: My lab's cheating a little bit. We are not looking at small molecules, we're looking at drugs. So we're trying to repurpose FDA approved drugs because I don't really develop drugs. Uh so that's that that's how we're skirting around this issue of like you develop a small molecule that's very effective in in vitro, you go into a patient doesn't it doesn't partition correctly in the body. What the heck's no, after 10 years of work, that's annoying. So we are we are we're cheating a little bit by uh just focusing right now on repurposing FDA approved drugs that have a huge literature. So the mechanism has been delved into in vitro, in animal models and in humans as much as we can. So um there's a way around that. Now, not every problem can, you know, uh we can't pull an FDA approved drug off the shelf for every single problem. That's not going to be feasible, but there's a good handful I think we can. ",
        "annotations": [
            {
                "present new idea": "Dylan introduces the idea of repurposing FDA-approved drugs as a way to circumvent the challenges of developing new small molecules, which addresses the broader discussion of translating in vitro results to in vivo applications.",
                "explain or define term or concept": "Dylan explains that his lab is 'cheating' by focusing on repurposing FDA approved drugs, clarifying that they are not developing new small molecules but rather finding new uses for existing, approved drugs.",
                "express frustation": "Dylan expresses frustration with the traditional drug development process, highlighting the annoyance of a small molecule being effective in vitro but failing in vivo after years of work."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: So, so one of the issues is uh like I said before, is delivery and imaging that delivery. And I know that there's a maybe handful of drugs that allow for that. In fact, if I start scratching my head and trying to name one, I probably wouldn't be able to. Uh there's something on the pet side that's available, I think, but nowhere else. Do you think that this is a an important issue to be able to to see what you're delivering and where? ",
        "annotations": [
            {
                "explain or define term or concept": "The speaker is defining the issue of delivery and imaging of that delivery as a key challenge, setting the stage for further discussion.",
                "ask clarifying question": "The speaker is asking if the ability to see what you're delivering and where is an important issue, seeking the group's opinion on the significance of this challenge."
            }
        ]
    },
    {
        "utterance": "mark sellmyer: I I can I can try to uh comment on that. I mean, I think the oldest uh sort of theranostic, maybe radioactive iodine for thyroid cancer. Because there you're getting a beta emission, which is killing the actual tumor and then or the thyroid in general and then you're also getting the uh gamma emission that you can detect with the camera. And so, um in my group, um you know, we've been interested in in uh well there's quite a there's quite a lot of efforts out there that are along these lines, especially the nanoparticle community, which can label, you know, things with both therapeutics and diagnostics. My group is stuck on the concept of uh reporter genes. And because GFP's been so critical to, you know, microscopy and biomedical applications and and study, you know, if we could develop good reporter genes for in vivo and human applications, that seems critically important to look at like living drug therapies. So cells that are being regenerative medicine for your cardiac myocytes or um you know, uh car T cells are a modern example, um virally delivered vectors another another example. And so, you know, to me on that front, if you can if you can image the delivery of these types of therapeutics that have different PK because they are tend to um sense and respond to pathology, that makes it a totally different problem than just what the admin characteristics are of a of uh chemotherapy or a biologic. So I think I think the idea is is ",
        "annotations": [
            {
                "provide supporting evidence": "The speaker provides radioactive iodine for thyroid cancer as an example of theranostics, supporting the idea of imaging delivery.",
                "expand on existing idea": "The speaker expands on the idea of delivery and imaging by mentioning nanoparticles and reporter genes as methods for imaging therapeutics, building on the previous discussion about the importance of seeing what you're delivering and where."
            }
        ]
    },
    {
        "utterance": "mark sellmyer: is really important and how do we develop things that are able to sense drug delivery. There's also the idea um from pet because I do pet on some of my day job that you can radio label the drug itself or something that's going to um show you whether or not you're inhibiting with therapeutic doses. So example of this is the estrogen receptor um and people have made drugs like full vestrant which are estrogen receptor degrader. So that drug binds to the estrogen receptor and it's got a hydrophobic group on it that targets the whole receptor to be degraded. ",
        "annotations": {
            "expand on existing idea": "The speaker is expanding on the previous discussion about the importance of delivery and imaging of drug delivery by suggesting ways to develop methods that can sense drug delivery.",
            "provide supporting evidence": "The speaker provides the example of estrogen receptor drugs like fulvestrant, which are estrogen receptor degraders, to support the idea of radio labeling drugs to show therapeutic effects."
        }
    },
    {
        "utterance": "mark sellmyer: Now if you make a estrogen receptor estradiol 4 and 18 probe, then you can use that to monitor the success of your estrogen receptor degrader in people. And so um people have have done this and it's becoming part of the standard of of drug development is try to try to develop companion diagnostic agents that are going to let you look at drug delivery and I'll stop. ",
        "annotations": {
            "provide supporting evidence": "Mark provides an example of using an estrogen receptor estradiol probe to monitor the success of an estrogen receptor degrader, supporting the idea of imaging drug delivery.",
            "expand on existing idea": "Mark expands on the idea of imaging drug delivery by providing a specific example of how it's being used in drug development to monitor therapeutic success."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, not not only drug delivery but also the the target engagement and dis disappearance of the target if that's the if that's the goal. ",
        "annotations": {
            "expand on existing idea": "This utterance expands on Mark Sellmyer's previous comment about imaging drug delivery by adding that it's also important to image target engagement and disappearance, building upon the discussion of imaging and controlling drug therapies."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um so so the word nano has been said several times. So um I I would like you guys to uh to give some thoughts about the future of nanotechnology in that regard. Um those of you who work in that area maybe want to speak a little bit. ",
        "annotations": {
            "encourage particpatioin": "Dr. Anna Moore is explicitly inviting those who work in nanotechnology to share their thoughts on the future of nanotechnology, building on the previous discussion where \"nano\" was mentioned several times."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, before can I comment on that? So before going to nanotechnology, I just wanted to add one more thing and it's that like the problems of the in vitro make sense from different angles when you look at it. I mean from the like the biological point of view, it makes perfect sense that they don't basically recapitulate what happens in vivo. ",
        "annotations": [
            {
                "expand on existing idea": "Morteza is adding to the discussion about the challenges of translating in vitro results to in vivo outcomes, which was initiated by Dr. Moore and further discussed by Crystal, Lisa, and Benjamin."
            }
        ]
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: But like from the physical point of view, it would be another story like different organs have different stiffness. They have like different properties and all of those things needs also to be considered in the in vitro setting. Like with the advances in the 3D bioprinting and like making like um uh pattern substrates that can basically provide opportunity for cells to basically make a 3D structures rather than like the flat surface uh 2D structured, all of those can be of a great help for getting more meaningful and robust in vitro data. So I think for that purpose maybe a group of scientists that have different looks into the same problem needs to collaborate to each other to basically make a perfect in vitro like setting that can be more close to the in vivo part. ",
        "annotations": [
            {
                "expand on existing idea": "Morteza expands on the discussion about in vitro models by introducing the physical properties of organs, such as stiffness, as important factors to consider, building on the previous discussion about the limitations of current in vitro models."
            },
            {
                "present new idea": "Morteza presents the idea of using 3D bioprinting and patterned substrates to create more realistic in vitro environments, which is a novel approach not explicitly mentioned before in the conversation."
            },
            {
                "propose decision": "Morteza proposes that scientists with different perspectives should collaborate to create better in vitro models, suggesting a concrete action for the group to consider."
            }
        ]
    },
    {
        "utterance": "mark sellmyer: I'll just say on that that frame too like it's not only to just do the study if you could or study basic biology, if you can start making better 3D culture systems and start to grow organs, there's also huge biomedical applications and treatments that can come out of it. ",
        "annotations": {
            "expand on existing idea": "Building on Morteza's point about improving in vitro models, Mark expands on the potential of 3D culture systems, suggesting that growing organs could lead to significant biomedical applications and treatments."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, exactly. These are basically the concept of the lab on a chip which basically again it's a kind of multidisciplinary thing. And for the nanotechnology, I mean, we are working in the field of nanomedicine for a couple of years and like one of the main problems that we have for delivery and also for like using them as a contrast agent is their interactions with biological systems. ",
        "annotations": {
            "expand on existing idea": "Morteza is building on the previous discussion about 3D culture systems and growing organs, adding that these concepts relate to the multidisciplinary field of lab-on-a-chip technology.",
            "present new idea": "Morteza introduces the problem of nanoparticles' interactions with biological systems as a major challenge in nanomedicine, which is a new topic in the discussion."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: So what happens is that what we makes in like laboratories are totally different from what we see like when they interact with the plasma proteins or any type of biological fluids. So what happens is that different types of biomolecules comes to the surface of nanoparticles and interact with them and basically form a corona around the surface of nanoparticles. So based on the type of the proteins, amount of the proteins, conformational changes of the proteins, basically we have totally different fate for the nanoparticles. So it can affect imaging, it can affect targeting, it can affect safety of the nanoparticles and those things basically needs to be considered in the imaging like procedures because you can imagine when you have additional layer at the surface of like nanoparticles, if you use that nanoparticles as a carrier, so what happens is that they can affect drug release. ",
        "annotations": [
            {
                "explain or define term or concept": "Morteza explains that nanoparticles behave differently in the lab versus in biological systems due to the formation of a protein corona, which affects their imaging, targeting, and safety, building on the previous discussion about nanotechnology and drug delivery."
            },
            {
                "provide supporting evidence": "Morteza provides evidence that the protein corona formed around nanoparticles affects their imaging, targeting, and safety, supporting the idea that the behavior of nanoparticles in the lab is different from their behavior in biological systems."
            }
        ]
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Or if you have like a fluorophore or something like that and what happens is that we may have like some unwanted interactions with those like labeling species that can affect the like the imaging capacity. So from a nanotechnology perspective, I would say we need more information about like the protein corona and how it can affect the safety and biological like fate of nanoparticles. ",
        "annotations": {
            "expand on existing idea": "Morteza is expanding on his previous point about the challenges of using nanoparticles as contrast agents, adding that unwanted interactions with labeling species can affect imaging capacity.",
            "provide supporting evidence": "Morteza provides supporting evidence by explaining how the protein corona can affect the imaging capacity of nanoparticles due to unwanted interactions with labeling species.",
            "present new idea": "Morteza presents the idea that more information is needed about the protein corona and how it affects the safety and biological fate of nanoparticles, which is a new direction for the discussion."
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So maybe also to follow up on Morteza's point um so in my research I focus a little bit more on using nanotechnology to manipulate the light. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "Lisa acknowledges Morteza's point, indicating she is building upon his contribution to the discussion about nanotechnology."
            },
            "expand on existing idea": {
                "Explanation": "Lisa expands on the discussion of nanotechnology by stating that her research focuses on using nanotechnology to manipulate light, building upon the previous discussion of nanotechnology."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So I think there is there's the whole field of you know, having nanoparticles in the body and and Morteza really nicely outlined also several of the challenges that come with that. Um and I think some of uh you know, what I think is kind of a new direction in using nanotechnology is actually um not necessarily having it interact directly in the body but having it manipulate the light with which you illuminate uh the part the biological species you want to see and actually then using light itself as a marker. ",
        "annotations": [
            {
                "acknowledge contribution": "Lisa acknowledges Morteza's contribution by stating that he nicely outlined several challenges of having nanoparticles in the body, recognizing his input on the topic.",
                "present new idea": "Lisa presents a new direction in nanotechnology, suggesting manipulating light to illuminate biological species instead of direct interaction with the body, introducing a novel concept."
            }
        ]
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: Um and some of the things I I'd also love to get people's perspective on there is um for example also as Morteza was saying, there are new ways where you can better um model the tissue in three dimensions and actually get effects such as the extracellular matrix um and and for instance in breast cancer metastasis, the extracellular matrix actually plays a really critical role. So um I'm curious to know how do people image that today because I think using sophisticated nano optics it would be potentially possible to monitor that. ",
        "annotations": {
            "expand on existing idea": "Lisa builds on Morteza's point about the importance of modeling tissue in three dimensions, adding that the extracellular matrix plays a critical role in breast cancer metastasis.",
            "ask clarifying question": "Lisa asks how people image the extracellular matrix today, showing that she is requesting more information on the topic.",
            "encourage particpatioin": "Lisa is asking for other people's perspectives on how to image the extracellular matrix."
        }
    },
    {
        "utterance": "mark sellmyer: It's a great question how to image the matrix. There aren't great tools as I understand. Maybe someone else knows. I think there's some MR techniques and someone MR might be Molly can jump in and correct me but I think there are ways to look at like higher how hyaluronic acid or you know, things that are around but I I don't know too much that's um specific to ECM like imaging collagen. I mean, I guess the other other techniques that come to mind are like MR elastography that's like Yeah and and ultrasound sort of stiffness measurements. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "Mark acknowledges Lisa's question about imaging the matrix as a great question."
            },
            "encourage particpatioin": {
                "Explanation": "Mark encourages Molly to participate by asking her to correct him if he is wrong about MR techniques."
            },
            "explain or define term or concept": {
                "Explanation": "Mark explains MR elastography and ultrasound as techniques for stiffness measurements."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Yeah. ",
        "annotations": {
            "express agreement": "Mark Sellmyer is agreeing with the previous statement about MR elastography and ultrasound stiffness measurements being techniques to image the matrix."
        }
    },
    {
        "utterance": "mark sellmyer: Just some extent you oh go ahead. ",
        "annotations": {
            "encourage particpatioin": "Mark encourages someone else to speak, as he says \"oh go ahead\"."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Talk to me. ",
        "annotations": [
            {
                "encourage particpatioin": "Dr. Moore is inviting someone to speak, continuing the discussion about imaging the matrix after Mark Sellmyer's comments."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: I was just going to say that, you know, perfusion and diffusion imaging goes this it's in the same category. ",
        "annotations": {
            "expand on existing idea": "Dr. Anna Moore is expanding on the discussion about imaging techniques, adding perfusion and diffusion imaging to the category of methods being discussed."
        }
    },
    {
        "utterance": "Benjamin Bartelle, ASU: Well, to some extent you can use MRscopy. Um people have picked up hyaluronic acid that way, but it's only for things that are highly um highly present there. So what is the signaling space of the ECM, what kind of cytokines have been decorating the ECM, all that stuff is kind of beyond the reach of clinical imaging without a biopsy. ",
        "annotations": [
            {
                "expand on existing idea": "This utterance expands on Mark Sellmyer's previous comment about imaging the extracellular matrix (ECM) by suggesting MR spectroscopy as a technique to image hyaluronic acid, which is part of the ECM."
            },
            {
                "provide supporting evidence": "Benjamin provides supporting evidence by stating that MRscopy has been used to detect hyaluronic acid, but only when it is highly present."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, lactate. ",
        "annotations": {
            "expand on existing idea": "Dr. Anna Moore says \"Yeah, lactate\" which builds upon the previous discussion about imaging the extracellular matrix (ECM) and the limitations of current techniques like MRscopy, suggesting lactate as another component that can be imaged, expanding on the discussion of what can be observed in the ECM."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah. ",
        "annotations": {
            "express agreement": "Dr. Anna Moore says \"Yeah\" in response to Benjamin Bartelle's statement that MRscopy can be used to some extent, indicating agreement with his point."
        }
    },
    {
        "utterance": "mark sellmyer: Yeah, I mean, I I think like as a big field a big wide open blue ocean of research really is the extracellular space because we know so much about cell biology, but like we don't really even know what happens to proteins very well once they get in the extracellular space, especially in the animal. So uh and it's very it's a challenging field, right? Because it's hard to um model that in in as we got this comes full circle back to the culture conditions question. ",
        "annotations": {
            "expand on existing idea": "This utterance expands on the discussion about imaging the extracellular matrix (ECM), which Lisa Poulikakos brought up, by highlighting the ECM as a significant area for research.",
            "provide supporting evidence": "The speaker supports the claim that the extracellular space is a wide open field of research by stating that we know a lot about cell biology but not what happens to proteins in the extracellular space, especially in animals.",
            "express agreement": "The speaker agrees with the previous discussion about the challenges of modeling the extracellular space in culture conditions."
        }
    },
    {
        "utterance": "mark sellmyer: Tough. ",
        "annotations": {
            "express frustation": "Mark expresses frustration at the challenges of modeling the extracellular space in culture conditions, which was the topic of the discussion."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, so I I think that uh at the end of this um at the end of the session we will need to produce some ",
        "annotations": {
            "propose decision": "Dr. Anna Moore is suggesting a concrete task for the group, which is to produce something at the end of the session, indicating a proposed decision."
        }
    },
    {
        "utterance": "Dr. Anna Moore: ideas and some hard pressing questions, uh what is on the way from translating things um from models to humans. ",
        "annotations": {
            "propose decision": "Dr. Anna Moore is suggesting that the group should produce ideas and hard-pressing questions about translating models to humans, which is a concrete choice for the group to focus on."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um in in all those various areas, not just, you know, drug delivery but just imaging. Even translating imaging agents uh that also requires some jumping through the loops. ",
        "annotations": {
            "expand on existing idea": "This sentence expands on the previous discussion about translating findings from models to humans, specifying that the challenges apply not only to drug delivery but also to imaging agents, building on the topic of translation challenges.",
            "present new idea": "The speaker presents the idea that translating imaging agents also requires overcoming obstacles, introducing a new aspect of the translation problem beyond just drug delivery."
        }
    },
    {
        "utterance": "Sixian You | MIT: Yeah, I'm really curious to know like um why why it takes 10 years, this is a very naive question. Why it takes 10 years to develop drugs and uh why it takes uh thousands of millions. ",
        "annotations": [
            {
                "ask clarifying question": "Sixian is asking a question to understand why drug development takes so long and costs so much, showing a desire for clarification on the overall process."
            }
        ]
    },
    {
        "utterance": "mark sellmyer: I guess how much clinicians get paid, it's uh, you know. ",
        "annotations": {
            "express humor": "Mark makes a joke in response to Sixian's question about the high cost and long time it takes to develop drugs, implying that clinician salaries contribute to the expense."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. Sorry guys, it's a big part of it. ",
        "annotations": {
            "express humor": "Benjamin is responding to Mark's comment about the cost of drug development, and he jokingly suggests that clinicians' salaries are a significant factor, expressing humor."
        }
    },
    {
        "utterance": "mark sellmyer: As the as the clinician on the call, I can't defend anything here, but I guess the um, the the thing that strikes me is is the sheer just amount of research that needs to go in to validate safety and the amount of time that that takes and effort. ",
        "annotations": {
            "explain or define term or concept": "Mark explains that a significant reason for the long drug development timeline is the extensive research required to validate safety, which takes considerable time and effort, in response to Sixian's question about the 10-year drug development timeline."
        }
    },
    {
        "utterance": "mark sellmyer: And then doing, you know, to get something to as an imaging probe, it's actually frankly somewhat markedly easier to get into the clinic than it is for a therapeutic where imaging probes generally are benign, right? They're not going to kill you, a radio tracer is low, MR contrast agents may be harder. ",
        "annotations": {
            "provide supporting evidence": "Mark provides supporting evidence for why imaging probes are easier to get into the clinic than therapeutics, stating that imaging probes are generally benign and not likely to kill you.",
            "explain or define term or concept": "Mark explains the difference in clinical translation difficulty between imaging probes and therapeutics, highlighting the relative ease of getting imaging probes approved due to their benign nature compared to therapeutics."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Somehow we've convinced people of this. Yeah, it's amazing. But yeah. ",
        "annotations": {
            "express humor": "Benjamin is making a joke about how people have been convinced that imaging probes are benign, even though they may not be, following Mark's comment that imaging probes are generally benign and don't kill you."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, yeah, because, you know, radio tracer, you inject them in such a small, small quantity that, you know, it's. ",
        "annotations": {
            "provide supporting evidence": "Dr. Anna Moore explains why radiotracers are considered safe by stating that they are injected in small quantities, supporting the idea that imaging probes are generally benign as Mark Sellmyer mentioned."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh yeah, I'm talking about Gadolinium. That's just. ",
        "annotations": {
            "express humor": "Benjamin is making a humorous remark about Gadolinium, likely referencing concerns or debates around its safety as an imaging agent, following a discussion about the relative ease of getting imaging probes versus therapeutics approved."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, Gadolinium. ",
        "annotations": {
            "express agreement": "Dr. Anna Moore expresses agreement with Benjamin's comment about Gadolinium."
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's some reason it's okay to put in millimolar amounts of Gadolinium into a person. ",
        "annotations": {
            "express humor": "Benjamin expresses humor about the acceptance of injecting millimolar amounts of Gadolinium into a person, following a discussion about the challenges of translating drugs and imaging agents from models to humans and the relative ease of getting imaging probes into the clinic compared to therapeutics."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, there's a warning on the label. ",
        "annotations": {
            "express humor": "Dr. Anna Moore's statement \"Well, there's a warning on the label\" is a humorous remark in response to Benjamin's comment about the safety of Gadolinium, implying that the warning label is insufficient to address the concerns."
        }
    },
    {
        "utterance": "Benjamin Bartelle: The debate the debate rages, yeah. ",
        "annotations": {
            "express humor": "Benjamin makes a humorous comment about the ongoing debate regarding the safety of Gadolinium, following a discussion about the challenges of translating drugs and imaging agents from models to humans and the relative ease of getting imaging probes into the clinic."
        }
    },
    {
        "utterance": "mark sellmyer: But but I think, you know, the therapeutic index for a therapy is a huge deal, right? If you you don't want to be causing toxicity and in the realm of do no harm, right? It it just takes us. ",
        "annotations": {
            "provide supporting evidence": "The speaker is providing reasoning to support the claim that drug development takes a long time, mentioning the importance of the therapeutic index and avoiding toxicity, which relates to the previous question about the long drug development timeline."
        }
    },
    {
        "utterance": "mark sellmyer: So so Sian, I I I don't know how to answer the question other than to say like as imagers, we actually are in a better position of um, getting things translated. ",
        "annotations": {
            "explain or define term or concept": "Mark is explaining to Sixian, who asked why drug development takes so long, that imaging agents are easier to translate than therapeutics because they are generally benign.",
            "express agreement": "Mark agrees with the implicit idea that imaging agents are easier to translate."
        }
    },
    {
        "utterance": "mark sellmyer: So like, you know, this was there's image guided therapies being here. People have developed fluorescent probes to thing like folate receptor or looking at um ICG for various lung cancers. So people have taken, you know, molecular imaging approaches and put those into patients without a huge, you know, long, long time to get those um, we're talking years rather than 10 years maybe to do this. ",
        "annotations": {
            "provide supporting evidence": "Mark provides examples of image-guided therapies and fluorescent probes targeting folate receptors and ICG for lung cancers, supporting his claim that imaging agents can be translated to patients faster than therapeutics, addressing Sixian's question about the long drug development timeline.",
            "expand on existing idea": "Mark expands on his previous point about the easier translation of imaging agents by providing specific examples of fluorescent probes used in image-guided therapies, building on the discussion about the challenges of drug development and translation.",
            "express enthusiasm": "Mark expresses enthusiasm by highlighting the progress in molecular imaging approaches and their relatively faster translation into clinical applications, contrasting it with the longer timelines associated with drug development."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, but you know, answering your question uh Sian is um, you know, just just look at the catalog from uh Charles River, you know, how much you pay for a transgenic animal. You know, it's like 250 bucks for one mouse. ",
        "annotations": {
            "explain or define term or concept": "Dr. Anna Moore is explaining the high costs of research by referencing the price of a transgenic animal from Charles River, providing a concrete example to illustrate the expense involved in translational research, which is in response to Sixian's question about the high cost of drug development."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's a deal. ",
        "annotations": {
            "express humor": "Benjamin expresses humor after Dr. Anna Moore mentions the cost of a transgenic animal, implying it's a good price."
        }
    },
    {
        "utterance": "Benjamin Bartelle: We transgenic GQ animals, 400 bucks anyway. ",
        "annotations": [
            {
                "express humor": "Benjamin is making a joke about the cost of transgenic animals, adding a humorous comment to the discussion about the cost of drug development."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: I know. I'm with you, I'm with you. I know. And yeah, those are even higher. And then you need n equals more than three, right? To do anything, you know, anything meaningful. And then um, all the antibodies and everything, and then once you're done with the with the with the pre-clinical studies in your lab. ",
        "annotations": {
            "provide supporting evidence": "Dr. Anna Moore is providing supporting evidence for why drug development is expensive, stating that transgenic animals are expensive and you need a large sample size to get meaningful results.",
            "express agreement": "Dr. Anna Moore expresses agreement with Benjamin's comment about the cost of transgenic animals."
        }
    },
    {
        "utterance": "Dr. Anna Moore: You go to CROs, uh, which are contract research organizations to do tox, to do PKPD, that's all required by FDA. And I hate to show you the bills from those companies because I went through that with my uh, with the compound that we're developed. You just, you know, basically wondering, you know, how can you possibly pay for all that? So, and then, uh, the companies that, you know, they invest money in this and then they want to recover those money and then we're wondering why the drugs are so expensive because if so much money you want to recover it somehow, right? ",
        "annotations": [
            {
                "explain or define term or concept": "CROs, tox, and PKPD are explained as contract research organizations, toxicology studies, and pharmacokinetics/pharmacodynamics studies, respectively, to clarify the process of drug development."
            },
            {
                "express frustration": "Dr. Anna Moore expresses frustration about the high costs associated with contract research organizations (CROs) and the overall expense of drug development, highlighting the financial burden and its impact on drug prices."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: There's a ray of light. ",
        "annotations": {
            "express enthusiasm": "Benjamin expresses optimism or encouragement, possibly in response to the discussion about the challenges and costs of drug development, suggesting a positive outlook despite the difficulties."
        }
    },
    {
        "utterance": "Benjamin Bartelle: And that this builds on something Dylan brought up earlier is um, you were saying you're using clinically approved drugs in your your studies and that sort of gives you a shortcut, right? With the 90% of investment in new medicines is in biologic drugs. Most of these are antibody based drugs, right? And they're going after specific targets. ",
        "annotations": [
            {
                "expand on existing idea": "Benjamin is expanding on Dylan's earlier point about using clinically approved drugs, adding that this approach provides a shortcut and that most new medicines are biologic, antibody-based drugs targeting specific targets."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: Like I made an antibody against this target, antibody against that target, I've proved that it's focal enough where it doesn't cause the worst side effects. Because of the modularity of nanotechnology and biological systems, the what everyone is doing right now, at least in the synthetic biology space, is they're starting with that. like we know this biologic drug hits this target safely. And so now we're going to build a car T cell therapy around that biologic drug. ",
        "annotations": [
            {
                "expand on existing idea": "This utterance expands on the previous discussion about the high cost and time associated with drug development by explaining how researchers are leveraging existing knowledge of safe biologic drugs to develop new therapies like CAR T-cells, thus building on the idea of finding shortcuts in drug development."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: We know that this drug goes hits T cells specifically. Great, we're building a theragnostic that's going to find the T cells and report back to us that it's done a job in it. So we have there is a way of bypassing some of that initial safety testing if you do go with these um biologics or just antibodies that are already approved. So there there's some hope there and I think the as we get better and better at this, we may start building out something like a grass list, you know, it's like generally recognized as safe list. ",
        "annotations": [
            {
                "expand on existing idea": "Building on the previous discussion about the high cost and time associated with drug development, Benjamin expands on the idea of using clinically approved drugs to bypass some initial safety testing, suggesting the development of theragnostics based on known biologics to reduce development time and cost."
            },
            {
                "present new idea": "Benjamin introduces the idea of creating a \"generally recognized as safe\" (GRAS) list for biological drugs, similar to the GRAS list used for food additives, to streamline the development and approval process for new therapies."
            },
            {
                "express enthusiasm": "Benjamin expresses optimism about the potential for nanotechnology and synthetic biology to leverage existing knowledge of safe biologics to accelerate the development of new therapies and theragnostics."
            }
        ]
    },
    {
        "utterance": "mark sellmyer: Good points. ",
        "annotations": {
            "acknowledge contribution": "Mark Sellmyer acknowledges Benjamin Bartelle's points, indicating he recognizes the value of the contribution to the discussion about drug development and safety testing."
        }
    },
    {
        "utterance": "Dr. Anna Moore: But but I'm still wondering if, you know, wouldn't it be great if every single drug that you uh inject has somewhat some kind of an image image guided guidance image guiding properties. So you can monitor this drug. ",
        "annotations": {
            "present new idea": "Dr. Anna Moore introduces the idea that it would be beneficial if all injectable drugs had image-guiding properties to allow for monitoring."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, without sacrificing, you know, many, many animals. And avoiding those costly studies that you have to pay for because you can actually do it yourself. ",
        "annotations": {
            "present new idea": "Dr. Anna Moore suggests a new idea of monitoring drugs without sacrificing animals and avoiding costly studies, building upon the discussion about the challenges and costs associated with drug development.",
            "expand on existing idea": "This utterance expands on the existing idea of image-guided properties for drugs, suggesting that it could reduce the need for animal testing and expensive studies, which was brought up in the context of the high costs and long timelines of drug development."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Because you can get quantitative data. ",
        "annotations": {
            "provide supporting evidence": "This statement provides a reason for the previous statement about the benefits of image-guided drugs, suggesting that quantitative data can be obtained, which supports the idea of monitoring drugs without sacrificing animals or costly studies."
        }
    },
    {
        "utterance": "Sixian You: So what I'm hearing is that uh, so for therapies, the major barrier is actually in biology is in in the therapies. ",
        "annotations": {
            "explain or define term or concept": "Sixian is summarizing the discussion, stating that the major barrier for therapies is in biology, specifically within the therapies themselves, to ensure understanding."
        }
    },
    {
        "utterance": "Sixian You: It's not image guiding technologies. But if we want to develop image guiding technologies, it will be helpful to develop something that can monitor these early changes induced by the drugs. ",
        "annotations": {
            "present new idea": "Sixian suggests developing image guiding technologies to monitor early changes induced by drugs, which is a novel idea in the context of the discussion about the challenges of drug development.",
            "expand on existing idea": "Sixian expands on the discussion about the challenges in drug development by suggesting that developing image guiding technologies to monitor early changes induced by drugs would be helpful, building upon the previous discussion about the need for better drug monitoring and delivery."
        }
    },
    {
        "utterance": "Sixian You: So either is the delivery of the. ",
        "annotations": {
            "expand on existing idea": "Sixian is building upon the previous discussion about the challenges in drug development and the potential benefits of image-guided therapies, and is about to suggest that image guiding technologies can help monitor early changes induced by drugs."
        }
    },
    {
        "utterance": "Dr. Anna Moore: With companion diagnostics. ",
        "annotations": {
            "expand on existing idea": "Dr. Anna Moore is expanding on Sixian You's idea about developing image guiding technologies, adding that it should be done with companion diagnostics, which was mentioned earlier by Mark Sellmyer."
        }
    },
    {
        "utterance": "Sixian You: Companion diagnostics. ",
        "annotations": {
            "confirm decision": "Sixian You confirms Dr. Anna Moore's suggestion of 'companion diagnostics', indicating agreement with the proposed term."
        }
    },
    {
        "utterance": "Molly Bright: Can I weigh in on a completely different take on on I guess yeah. ",
        "annotations": {
            "encourage particpatioin": "Molly is inviting herself to contribute to the discussion, which encourages participation from others."
        }
    },
    {
        "utterance": "Molly Bright: So I think about it from the other end and I guess I'm surrounded by very long-term treatments and also ambiguous treatments. So there are so many therapeutics and drugs that we use in humans that may or may not work for someone, we don't know how to dose it and we don't have an imaging marker of what it's doing particularly in the brain. ",
        "annotations": [
            {
                "present new idea": "Molly introduces the idea of approaching the problem from the perspective of long-term and ambiguous treatments, which is a new angle in the discussion.",
                "express frustration": "Molly expresses frustration with the ambiguity and lack of imaging markers for many treatments used in humans, highlighting a significant problem in current therapeutic approaches."
            }
        ]
    },
    {
        "utterance": "Molly Bright: Um, so that's that's my domain would be the brain, that's unfortunately what I can focus on. But there are so many drugs that I think sit into this category and if you think of all of the mood disorders and anything to do with mental health, anything to do with long-term degeneration of neural function uh and and dementia. ",
        "annotations": {
            "expand on existing idea": "Molly is expanding on the previous discussion about drug development and imaging by focusing on the specific challenges in her domain, which is the brain and related disorders.",
            "express frustration": "Molly expresses frustration with the limitations in treating brain-related disorders, highlighting the lack of effective treatments and imaging markers."
        }
    },
    {
        "utterance": "Molly Bright: We need a time scale of looking at. ",
        "annotations": {
            "present new idea": "Molly is introducing a new idea about the need for a time scale when looking at treatments, especially in the context of long-term treatments and ambiguous treatments for brain-related disorders."
        }
    },
    {
        "utterance": "Molly Bright: What a drug does and what happens in the absence of that drug in the face of huge human variability to evaluate if we're remotely close to getting after what we're after. ",
        "annotations": {
            "present new idea": "Molly introduces the idea of evaluating the effect of a drug by comparing its effects to the absence of the drug, especially considering human variability, which is a novel concept in the context of the discussion.",
            "explain or define term or concept": "Molly is explaining the concept of evaluating drug efficacy by comparing outcomes with and without the drug, considering human variability, to ensure the treatment is effective.",
            "propose decision": "Molly proposes that to evaluate if we're remotely close to getting after what we're after, we need to compare what a drug does to what happens in its absence, considering human variability."
        }
    },
    {
        "utterance": "Molly Bright: And that is a huge cost. ",
        "annotations": {
            "express frustation": "Molly is expressing frustration about the huge cost associated with evaluating the effectiveness of drugs, especially in the context of long-term treatments and human variability, building on her previous points about the need for long-term monitoring and the challenges in treating mood disorders and dementia."
        }
    },
    {
        "utterance": "Molly Bright: Sorry, downer. ",
        "annotations": {
            "express humor": "Molly Bright is making a self-deprecating joke about her previous comments being negative."
        }
    },
    {
        "utterance": "mark sellmyer: Well, I don't know. ",
        "annotations": {
            "express alternative decision": "Mark is responding to Molly's statement that was a 'downer' and he is disagreeing with her sentiment."
        }
    },
    {
        "utterance": "mark sellmyer: Is hyperpolarized a way forwards to look at function in the brain using hyperpolarized substrates with MRI? ",
        "annotations": {
            "present new idea": "Mark is presenting a new idea by suggesting hyperpolarized MRI as a way to look at brain function, which hasn't been discussed before in this specific context."
        }
    },
    {
        "utterance": "Molly Bright: Is that really going to get at the. ",
        "annotations": {
            "ask clarifying question": "Molly is asking a clarifying question about whether hyperpolarized substrates with MRI can really get at the function in the brain, following Mark's suggestion."
        }
    },
    {
        "utterance": "Molly Bright: The limitation of this scale of treatment efficacy? Yeah. ",
        "annotations": [
            {
                "ask clarifying question": "Molly is asking if hyperpolarized substrates with MRI will address the limitations of treatment efficacy, following Mark's suggestion of using it to look at function in the brain."
            }
        ]
    },
    {
        "utterance": "mark sellmyer: Right. So so efficacy as measured by some um, for psychiatric disease. ",
        "annotations": {
            "explain or define term or concept": "Mark is explaining the concept of efficacy in the context of psychiatric disease, which is relevant to the discussion about drug development and imaging markers."
        }
    },
    {
        "utterance": "mark sellmyer: Really hard to measure, well, harder to measure than let's say a tumor size, you know. ",
        "annotations": {
            "explain or define term or concept": "Mark is explaining that efficacy for psychiatric disease is harder to measure than tumor size, which is a concept related to the challenges in drug development and imaging discussed earlier."
        }
    },
    {
        "utterance": "Benjamin Bartelle: almost worse that we have the wrong. ",
        "annotations": [
            {
                "express frustration": "Benjamin expresses frustration about having the wrong [measurements], which is related to the difficulty of measuring efficacy, especially in psychiatric diseases, as discussed by Mark and Molly."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: metrics, right? Like Biogen Idec just spent a billion dollars on this drug that reduces Alzheimer's plaques and it worked in mice and it works in people. It reduces the Alzheimer's plaque, doesn't do anything else. You still have Alzheimer's, you just don't see the plaques as bad anymore. And so they're image guided biomar, their imaging biomarker was absolutely wrong and they were completely all in on it and they're still trying to get it to work. So so you can really get led astray with these things, yeah. ",
        "annotations": [
            {
                "provide supporting evidence": "Benjamin provides an example of Biogen Idec's drug that reduces Alzheimer's plaques but doesn't cure the disease, supporting the idea that current metrics and biomarkers can be misleading in drug development."
            },
            {
                "offer constructive criticism": "Benjamin critiques the use of Alzheimer's plaques as a biomarker, suggesting that it's a wrong metric that can lead research astray, implying a need for better biomarkers."
            }
        ]
    },
    {
        "utterance": "Molly Bright: Any anything positive to say in this direction to balance what I've done to the conversation? ",
        "annotations": {
            "express humor": "Molly is making a self-deprecating joke about bringing the conversation down, expressing humor."
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's a world of opportunity. ",
        "annotations": {
            "express enthusiasm": "Benjamin expresses enthusiasm, ending the discussion on a positive note after a somewhat pessimistic discussion about drug development and treatment efficacy."
        }
    },
    {
        "utterance": "Lisa Poulikakos: understanding. So maybe on Ben's point. So basically this drug reduced the plaques in Alzheimer's and in mice it also reduced symptoms but in humans it didn't reduce symptoms. Is that correct? ",
        "annotations": {
            "ask clarifying question": "Lisa is asking for confirmation on her understanding of Ben's point about the drug reducing plaques in Alzheimer's but not symptoms in humans, to ensure she has grasped the details correctly."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. That's Aducanumab is the story there. ",
        "annotations": {
            "acknowledge contribution": "Benjamin acknowledges Lisa's understanding of the situation with Aducanumab, referencing the previous discussion about the drug's effects on Alzheimer's plaques and symptoms."
        }
    },
    {
        "utterance": "Lisa Poulikakos: Okay, interesting. And does are there any ideas why or it's completely unknown? ",
        "annotations": {
            "ask clarifying question": "Lisa asks for the reasons why the drug reduced plaques in Alzheimer's but did not reduce symptoms in humans, following up on Ben's statement about the drug Aducanumab."
        }
    },
    {
        "utterance": "Benjamin Bartelle: The the amyloid hypothesis um was you know super popular this gets back to Crystal's original point, which is uh people get hung up stuck on these mechanisms and they seem to be what you're after and in mice these amyloid plaques removal of the amyloid plaques was highly correlated with the um positive outcomes in these Alzheimer's models. We don't know if the Alzheimer's models are accurate. We don't know if Alzheimer's plaques that you see are anyway like related directly to Alzheimer's in humans. Uh human patients often have Alzheimer's plaques. They often have Alzheimer's plaques and no Alzheimer's. They sometimes have no plaques and Alzheimer's. So it was enough it was enough to go on where the animals model animal models worked. So it was worth pursuing because they were getting good data here and they could see their imaging biomarker in humans work. But it turned out or ",
        "annotations": [
            {
                "expand on existing idea": "This utterance expands on the discussion about the challenges of translating findings from animal models to humans, specifically using the example of the amyloid hypothesis in Alzheimer's research, which was brought up by Crystal earlier."
            },
            {
                "provide supporting evidence": "The speaker provides the example of the amyloid hypothesis and the drug Aducanumab to support the idea that focusing solely on mechanisms that work in animal models can be misleading, as the drug reduced plaques in humans but did not improve symptoms."
            }
        ]
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": [
            {
                "express enthusiasm": "Lisa expresses surprise or disbelief at the information shared about the Alzheimer's drug Aducanumab not reducing symptoms in humans despite reducing plaques, indicating a strong reaction to the unexpected outcome."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: I mean the case is still they're still making their case. There's their other companies based on the same amyloid hypothesis still testing the same thing. There may be some condition where it works but as yet it it does not work. So ",
        "annotations": {
            "reject idea": "Benjamin is rejecting the amyloid hypothesis as a viable treatment for Alzheimer's, based on the failure of Aducanumab, but acknowledges that companies are still pursuing it."
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": [
            {
                "express enthusiasm": "Lisa expresses strong surprise or disbelief at the information shared about the Alzheimer's drug Aducanumab not working in humans despite reducing plaques, indicating a strong reaction to the unexpected outcome."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: Where did they go wrong? Did they go wrong in dish where they saw these amyloid plaques and got completely locked in on it? Did they go wrong in their animal models? Is that actually relevant to mice where the plaques are important for mice and cured them? Or is there something else going on in humans where we're just not seeing that part? Like we're getting half of it. You have it's maybe it's necessary but not sufficient. We don't know any of that stuff yet just because the human work is so slow and the one molecular marker we spent so much time on, you know these great pet tracers for Alzheimer's plaques. ",
        "annotations": {
            "ask clarifying question": "Benjamin is questioning the validity of the approach taken in Alzheimer's research, specifically asking where the researchers might have gone wrong in their methodology, such as in vitro studies or animal models, given the drug's failure in humans, which is a request for explanation.",
            "express frustration": "Benjamin expresses frustration with the current state of Alzheimer's research, highlighting the slow progress and the reliance on a molecular marker (amyloid plaques) that may not be directly relevant to the disease in humans, which shows dissatisfaction with the current metrics."
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. Why? Oh, that's yeah, amazing. ",
        "annotations": [
            {
                "express enthusiasm": "Lisa expresses enthusiasm after hearing about the failure of a drug that reduces Alzheimer's plaques but doesn't alleviate symptoms, possibly indicating surprise or interest in the unexpected outcome."
            },
            {
                "ask clarifying question": "Lisa asks 'Why?' after hearing about the drug's failure, seeking further explanation about the reasons behind the unexpected outcome of the Alzheimer's drug."
            }
        ]
    },
    {
        "utterance": "Molly Bright: I I mean maybe one way to distill one of these issues is the time scale of knowing efficacy in humans is way too long. Um I don't know how like is there a way to work backwards? I I'm I'm not sure. Um but to to always go from small to big could mean that an entire direction is not wasted but mistargeted. ",
        "annotations": {
            "express frustration": "Molly expresses frustration with the long time scale required to determine drug efficacy in humans, building on the previous discussion about the challenges of translating findings from models to humans and the high costs and time associated with drug development.",
            "present new idea": "Molly presents a new idea of working backwards to determine efficacy, suggesting a different approach to the current method of going from small to big, which could lead to mistargeted efforts."
        }
    },
    {
        "utterance": "Benjamin Bartelle: What if the mechanism for Alzheimer's the disease progression in Alzheimer's in human beings has never actually been seen because you can't recapitulate it in a dish and you can't recapitulate it in a mouse. I don't I don't know but what if that's true then everything we're doing is wrong in Alzheimer's. And as yet there are no there are no root cause treatments for any neurodegeneration and maybe it's because we're not seeing it because we're not looking in the right place. It's possible. A world of opportunity. ",
        "annotations": [
            {
                "present new idea": "Benjamin is presenting a novel idea that the mechanism for Alzheimer's disease progression in humans has never been seen because it cannot be replicated in a dish or a mouse, which is a new perspective in the conversation.",
                "express frustration": "Benjamin expresses frustration with the current state of Alzheimer's research, stating that everything being done is wrong and there are no root cause treatments for neurodegeneration, indicating dissatisfaction with the lack of progress.",
                "express enthusiasm": "Benjamin ends the utterance with \"A world of opportunity\", expressing enthusiasm for the potential to discover new approaches to understanding and treating Alzheimer's."
            }
        ]
    },
    {
        "utterance": "Molly Bright: We'll always have a job. Um but it's ",
        "annotations": [
            {
                "express humor": "Molly expresses humor by saying 'We'll always have a job' after a discussion about the challenges and failures in Alzheimer's drug development, implying job security for researchers due to the ongoing problems."
            }
        ]
    },
    {
        "utterance": "Mark Sellmyer: Molly, I think your question is good about time scales, right? And the the very last question of our group 2.3 topic is can we integrate imaging across time to see the impact of a previous dosing over weeks to months or can you integrate, you know, biologic processes over time to capture something that might be a longer um longer in the making and longer in the resolution. It's tough. ",
        "annotations": [
            {
                "acknowledge contribution": "Mark acknowledges Molly's question about time scales is a good one, recognizing her input to the discussion.",
                "expand on existing idea": "Mark expands on Molly's question about time scales by relating it to the group's topic of integrating imaging across time to see the impact of dosing or biologic processes over weeks to months, adding more details to the discussion."
            }
        ]
    },
    {
        "utterance": "Crystal Rogers: There are people doing primate research to do exactly this, right? So there was a whole session that the ORIP had about the importance of primate research, which again still isn't the same, but at least it scales up to um to us as primates. But I think that is the same it's the same thing again, right? Super expensive, very time consuming, still not exactly the same physiology and there's no guarantee that it will directly translate to humans. So so I don't know what I said. I don't think I added anything, but I just wanted to bring that up again that it we do have a way to test um it's just it's not efficient and it's super hard. ",
        "annotations": [
            {
                "provide supporting evidence": "The speaker mentions primate research as a way to test the efficacy of treatments over longer time scales, supporting the idea of integrating imaging across time to see the impact of dosing.",
                "express alternative decision": "The speaker acknowledges primate research as a testing method, but expresses reservations about its efficiency, cost, and guaranteed translatability to humans, suggesting it may not be the best solution."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: Millions of dollars going into marmosets for this exact reason of like maybe if mice don't tell us, maybe marmosets will. Millions being invested. Every every big neuroscience lab in America is is putting together their marmoset program in the hopes that it's going to be relevant. ",
        "annotations": {
            "expand on existing idea": "This utterance expands on the previous discussion about the challenges of translating findings from model organisms (mice) to humans, suggesting that marmosets are being explored as a potentially more relevant model, as Crystal mentioned primate research.",
            "express enthusiasm": "The speaker expresses enthusiasm about the potential of marmosets as a model for neuroscience research, highlighting the significant investment being made in marmoset programs."
        }
    },
    {
        "utterance": "Mark Sellmyer: Right. ",
        "annotations": [
            {
                "express agreement": "Mark Sellmyer is agreeing with a previous statement, though the specific statement is not included in this utterance."
            }
        ]
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "present new idea": "Sixian is introducing a novel concept of using genetic reporters in human beings, which hasn't been explicitly discussed before in this specific context."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "express agreement": "Benjamin Bartelle expresses agreement with the idea of genetic reporters in human beings, which was proposed by Sixian You in the previous utterance."
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. It seemed impossible 10 years ago, but now with I mean everyone's everyone's getting into a cell based therapy and what do you how are you going to track those things? ",
        "annotations": {
            "expand on existing idea": "Mark is expanding on Sixian's question about genetic reporters in human beings, building on the idea of tracking cells.",
            "ask clarifying question": "Mark is asking how to track cell-based therapies, which is a clarifying question about the practicalities of using genetic reporters in humans."
        }
    },
    {
        "utterance": "Dylan Burnette: But what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. So so when Crystal was talking I was like, Yeah. ",
        "annotations": [
            {
                "express concern": "The speaker expresses concern about the public's perception of cell-based therapies, highlighting the potential fear and lack of understanding surrounding the introduction of modified or foreign cells into the body."
            }
        ]
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "express agreement": "Mark Sellmyer is agreeing with Dylan Burnette's previous statement about the public's perception of cell-based therapies."
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "present new idea": "Sixian is introducing a novel concept of using genetic reporters in human beings, which hasn't been explicitly discussed before in the conversation.",
            "ask clarifying question": "Sixian is asking a question to the group to get their opinion on the future of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "express agreement": "Benjamin Bartelle expresses agreement with Sixian You's question about the future of genetic reporters in human beings, indicating his positive view on the topic."
        }
    },
    {
        "utterance": "Mark Sellmyer: It's like that. ",
        "annotations": {
            "express agreement": "Mark Sellmyer is agreeing with the previous statement about the potential of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. Let's do it. Let's go. ",
        "annotations": [
            {
                "express agreement": "Benjamin explicitly agrees with the idea of using genetic reporters in human beings, which was just proposed by Sixian."
            },
            {
                "express enthusiasm": "Benjamin expresses enthusiasm for the idea of using genetic reporters in human beings, building on the previous discussion about cell-based therapies and tracking them."
            }
        ]
    },
    {
        "utterance": "Crystal Rogers: It's a great idea, but that requires a massive effort in science communication. And so if people won't take a vaccine to save their lives, I don't know that anybody would want to have a reporter uh inside of them. So I think we have these issues here. We are all for it. Like inject me, go for it, but um so there have to there has to be a a front of us being the scientists and the clinicians and also explaining how important and innocuous some of these things can be. They can be helpful. They can be, you know, therapeutic. They can also be um diagnostic but or theragnostics, right? That's the the term. But ",
        "annotations": [
            {
                "acknowledge contribution": {
                    "Explanation": "The speaker acknowledges the previous suggestion of genetic reporters in human beings as a \"great idea\"."
                }
            },
            {
                "offer constructive criticism": {
                    "Explanation": "The speaker offers a critique by pointing out the need for massive science communication efforts, implying that the idea of genetic reporters in humans faces challenges due to public perception and hesitancy, drawing a parallel to vaccine hesitancy."
                }
            }
        ]
    },
    {
        "utterance": "Dylan Burnette: It's like that. It's yeah. ",
        "annotations": [
            {
                "express agreement": "Dylan Burnette's utterance \"It's like that. It's yeah.\" expresses agreement with the previous statement about the need for science communication regarding genetic reporters in human beings."
            }
        ]
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": [
            {
                "express agreement": "Mark Sellmyer is agreeing with a previous statement about the potential of genetic reporters in human beings."
            }
        ]
    },
    {
        "utterance": "Dylan Burnette: I I I ran into this yesterday. I was trying to I was trying to consent a patient to image their bacteria. And the question is is is your test going to help me in any way? Yeah. And the response is it can't because it's investigational as an imaging and diagnostic it will not change your management at all. The difference for the therapy folks is they're like we don't know. We're going to see it might help you. And so that's a huge like just big difference between therapeutic intervention trials and like diagnostic like, you know, approaches. Yeah. But but what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. ",
        "annotations": [
            {
                "express alternative decision": "The speaker is contrasting diagnostic approaches, which cannot guarantee help, with therapeutic interventions, which offer the possibility of benefit, expressing a preference for the latter."
            },
            {
                "express frustation": "The speaker expresses frustration about the public's potential fear of cell-based therapies and the lack of science communication, highlighting a challenge in translating scientific advancements to the general public."
            }
        ]
    },
    {
        "utterance": "Dylan Burnette: and that they shouldn't be, but maybe they should, right? ",
        "annotations": {
            "encourage particpatioin": "Dylan is encouraging participation by posing a question at the end of his statement, inviting others to share their thoughts on whether scientists should be the ones communicating science to the public."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, well, there's another approach, uh, you know, when you're talking about cell-based therapies and you need to track those cells, you don't necessarily have to have a permanent, you know, imaging reporter in your body, you could just label cells before you inject them with some kind of a label that is visible for the scanner, whether it's magnetic label, you know, I'm a nanoparticle person, so obviously, um, that's what what comes to mind, but also what's biodegradable and gets, you know, gets outside your body at some point. So that doesn't seem so scary, does it? ",
        "annotations": {
            "expand on existing idea": "Dr. Anna Moore expands on the discussion about genetic reporters in human beings by suggesting an alternative approach of labeling cells before injection with a visible and biodegradable label, addressing concerns about permanent imaging reporters.",
            "explain or define term or concept": "Dr. Anna Moore explains the concept of using magnetic labels for cell tracking, clarifying that she is a nanoparticle person and that this approach involves biodegradable labels that eventually leave the body.",
            "present new idea": "Dr. Anna Moore presents a new approach to cell-based therapies by suggesting labeling cells with a visible and biodegradable label before injection, as an alternative to permanent imaging reporters."
        }
    },
    {
        "utterance": "Benjamin Bartelle: longitudinally, I've I've had very little success with that. If you're trying to look at something over months, the chances you're going to find that nanoparticle laden T cell or that nanoparticle laden, you know, stem cell and have it persist over the months you need to follow the disease progression or therapy progression. Like we've been trying that for a long time since before I started grad school and it's just without having that genetic persistence, it hasn't worked. ",
        "annotations": {
            "provide supporting evidence": "Benjamin shares his experience of having little success tracking nanoparticle-laden cells longitudinally, suggesting that this approach may not be effective for long-term monitoring, which supports the need for genetic persistence mentioned by Dr. Anna Moore."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, I'm just saying like, you know, that's that's one problem with we can talk we can actually talk about that because our experience is that you could follow them for quite some time providing that cells do not divide because if they divide, then they dilute the material obviously. And and there has to be complementary methods to basically see the effect of your therapy. So you cannot kill, you know, many bunnies with one I I hate even saying that. That doesn't sound good. ",
        "annotations": [
            {
                "expand on existing idea": "Dr. Anna Moore expands on the previous discussion about cell-based therapies and tracking cells, mentioning that their experience shows cells can be followed for a while if they don't divide, which dilutes the labeling material."
            },
            {
                "provide supporting evidence": "Dr. Anna Moore provides supporting evidence based on their experience that cells can be followed for a considerable time if they do not divide, which would dilute the material."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: I've never heard this analogy, so. ",
        "annotations": {
            "express humor": "Benjamin expresses humor by commenting on Dr. Anna Moore's unusual analogy of \"killing many bunnies with one\"."
        }
    },
    {
        "utterance": "Dr. Anna Moore: No. So, um, okay, so we got a, we got a warning, uh, T minus 15 minutes till the end of our. ",
        "annotations": [
            {
                "None": "No code applies to this utterance as it is a transitional statement indicating the end of the session is approaching."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: So basically what I was trying to say, I think you need more than one modality and more than one imaging, uh, you know, to even monitor one process. It seems like, you know, it has to be several different approaches just to make sure that your cells are injected, that they get where they have to go, uh, how much get lost on the way, whether they're doing what they're supposed to do, uh, and whether there's any improvement. So like right there it's like 1.5, like four, four different things that you need to monitor and you need four different ways to do that. I don't believe that there is like this universal contrast agent that can, you know, you can inject it and it's going to monitor everything. It doesn't exist. So anyway, so, um, like I said, we have, uh, 14 minutes now. ",
        "annotations": [
            {
                "expand on existing idea": "Dr. Anna Moore expands on the discussion about translating models to humans by stating that multiple modalities and imaging approaches are needed to monitor a single process, building on the previous discussion about the challenges of drug delivery and imaging."
            },
            {
                "reject idea": "Dr. Anna Moore rejects the idea of a universal contrast agent that can monitor everything, stating that it doesn't exist, after discussing the need for multiple modalities to monitor cell-based therapies."
            }
        ]
    },
    {
        "utterance": "Sixian You: I just put down whatever I'm hearing. So I think for the next 10 minutes, can we just uh, uh, each say or just uh, input like what is the most exciting idea you heard in this meeting or you you are summarizing and we put three major ideas in in the chat instead of uh, everything. ",
        "annotations": {
            "propose decision": {
                "Explanation": "Sixian proposes that for the next 10 minutes, each participant should share the most exciting idea they heard during the meeting and summarize three major ideas in the chat, aiming to consolidate the discussion."
            },
            "encourage particpatioin": {
                "Explanation": "Sixian encourages everyone to share their thoughts on the most exciting ideas from the meeting, promoting active involvement from all participants."
            }
        }
    },
    {
        "utterance": "Sixian You: So, so summarizing, I think um, Anna said it pretty well, so it has to be a combination of multimodal approaches uh, for these four different processes. I hear the delivery process and then the efficacy process. The other two I didn't catch it. So. ",
        "annotations": {
            "expand on existing idea": "This utterance builds on Dr. Anna Moore's previous statement about the need for multimodal approaches, summarizing and reiterating the idea of combining different methods.",
            "acknowledge contribution": "The speaker acknowledges Dr. Anna Moore's contribution by stating that she said it pretty well, recognizing her input on the topic of multimodal approaches."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, the other thing is delivery process and then, uh, you want to be able to monitor what you delivered, if it's still there, if it's still intact, if it's still functioning. ",
        "annotations": {
            "expand on existing idea": "This utterance expands on Sixian's summary of the discussion by adding more detail to the processes that need to be monitored, building on the previous discussion about delivery and efficacy.",
            "explain or define term or concept": "Dr. Anna Moore explains the different aspects of the delivery process that need to be monitored, including whether the delivered substance is still present, intact, and functioning."
        }
    },
    {
        "utterance": "Dr. Anna Moore: You know, like say the cells, right? The cell therapy, uh, are they still functioning? Are they still like for example with islet transplantation, you put islets in the human body and 60% of them dead two weeks after transplantation. ",
        "annotations": [
            {
                "expand on existing idea": "Dr. Moore is expanding on the idea of monitoring cell therapies, building on the previous discussion about delivery and efficacy by adding the aspect of whether the delivered cells are still functioning."
            },
            {
                "provide supporting evidence": "Dr. Moore provides supporting evidence for the need to monitor cell therapies by giving the example of islet transplantation, where a significant percentage of transplanted cells die shortly after transplantation."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: And you don't know where they went, you don't know what they're doing, you don't know if they're producing insulin, you're blind completely. And each, uh, islet batch comes from a donor who's obviously deceased. ",
        "annotations": [
            {
                "express frustration": "Dr. Anna Moore expresses frustration about the lack of knowledge regarding the fate and function of transplanted islets, highlighting the challenges in monitoring their activity and location after transplantation."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: So it's just an example. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "This utterance acknowledges the preceding discussion and provides closure to the example being discussed, without necessarily agreeing or expanding on it."
            }
        }
    },
    {
        "utterance": "Sixian You: Mhm. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "Sixian You is acknowledging Dr. Anna Moore's last statement about islet transplantation and the challenges in monitoring their function after transplantation."
            }
        }
    },
    {
        "utterance": "Sixian You: One idea that I think is super exciting is this idea of long-term genetic reporters. It is high risk, it is very controversial, but um, but for auto imaging they provide really good contrast and they they're they're almost forever if they don't get injected, ejected out of the body. ",
        "annotations": {
            "present new idea": "Sixian is introducing the idea of long-term genetic reporters, which hasn't been explicitly discussed before as a solution, though reporter genes have been mentioned.",
            "express enthusiasm": "Sixian expresses excitement about the idea of long-term genetic reporters, indicating a positive outlook on its potential.",
            "provide supporting evidence": "Sixian supports the idea by stating that genetic reporters provide really good contrast for auto imaging and can last almost forever if they are not ejected from the body."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Genetic reporter, I'm all for it. I have one. Anyone wants it. ",
        "annotations": {
            "express agreement": "Benjamin explicitly agrees with the idea of genetic reporters that Sixian brought up in the previous utterance.",
            "express humor": "Benjamin makes a joke by saying he has a genetic reporter and asking if anyone wants it, which is intended to be funny."
        }
    },
    {
        "utterance": "Benjamin Bartelle: We bring up theranostic a lot. We've said that a number of times. Um, and it's the great thing to say, um, but what exactly is a theranostic when we go through it and it neither needs to be um, some nanotechnology, some macromolecular complex that is detectable and sensitive to a specific readout or it needs to be uh an engineered cell that uh is detectable and then can change its its signal or shape. You need to have that level of complexity to have a theranostic. ",
        "annotations": {
            "explain or define term or concept": "Benjamin is explaining the concept of a theranostic agent, specifying that it needs to be a detectable nanotechnology, macromolecular complex, or engineered cell that can change its signal or shape, which builds on the prior discussion of theranostics."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh, it has to be for the right mechanism. ",
        "annotations": {
            "expand on existing idea": "Benjamin is adding a condition to the idea of theranostics, expanding on the previous discussion about their potential by stating that they must be for the right mechanism."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think that was the thing. ",
        "annotations": {
            "express agreement": "Benjamin agrees with a point that was previously made, likely about the importance of the right mechanism for theranostics."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. ",
        "annotations": [
            {
                "acknowledge contribution": "Benjamin is acknowledging the previous statement made by Dr. Anna Moore, but he is not agreeing or expanding on it."
            }
        ]
    },
    {
        "utterance": "Dylan Burnette: But we haven't really talked too much about toxicity and the ability to actually detect uh tissue that is dying either through necrosis or apoptosis or some either programmed or not programmed cell death. It's something that is would be quite useful I think if you're putting drugs into people and then you want to drugs where they go where they go, but if they're causing damage along the way or when they get concentrated at the side of of where they're supposed to be at, it's hard to tell. Um, and I know in in in neurobiology if you actually saw the neurons dying that wouldn't be bad. ",
        "annotations": {
            "present new idea": {
                "Explanation": "Dylan introduces the idea of detecting tissue damage and cell death (necrosis, apoptosis) as a useful metric when administering drugs, which hasn't been discussed previously."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: So you're saying cell death as a target for our imaging and theranostic then. Like understanding that. Yeah, so if you had a read out to to to actually monitor uh the the target tissues uh actual death or not because sometimes in the case of cancer you want to kill these things, but sometimes you don't want to kill it. ",
        "annotations": {
            "expand on existing idea": "Benjamin is building on Dylan's idea of detecting tissue death by suggesting cell death as a target for imaging and theranostics, expanding on the potential applications of monitoring cell death in different contexts like cancer."
        }
    },
    {
        "utterance": "Dylan Burnette: So so it could be both targeted and just a general read out of toxicity because sometimes you don't want your cells to die. Um, as a matter of fact, I don't want more of my cells to die in general. ",
        "annotations": [
            {
                "expand on existing idea": "Dylan is expanding on the idea of monitoring cell death, which he introduced in the previous sentence, by specifying that it can be both targeted and general, depending on the context."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Well, a long time ago there was an an an ex in five probes developed, I would say 20 years ago to monitor tumor response to therapy. ",
        "annotations": {
            "provide supporting evidence": "Dr. Anna Moore mentions the existence of annexin V probes developed 20 years ago to monitor tumor response to therapy, providing a historical example relevant to the discussion of imaging and therapy monitoring."
        }
    },
    {
        "utterance": "Benjamin Bartelle: just like, oh, everything's ferroptosis, right? ",
        "annotations": {
            "express humor": "Benjamin Bartelle is making a joke about ferroptosis, likely in response to the discussion about cell death and toxicity."
        }
    },
    {
        "utterance": "Dylan Burnette: Um, but uh, but so it's it's probably impossible to have one particular marker to pull off, you know, actually knowing what kind of of cell death, but it would be nice to know if cells are alive or not inside of of a biotic. ",
        "annotations": {
            "expand on existing idea": "Dylan is expanding on the idea of monitoring toxicity and cell death, which was brought up by Benjamin, by stating that it would be useful to know if cells are alive or not inside a biotic environment.",
            "present new idea": "Dylan presents the idea that it would be nice to know if cells are alive or not inside of a biotic environment, which is a new consideration in the context of monitoring cell death."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. So, um, so let's see. So, um, Sision, do you do you feel comfortable talking about those things? ",
        "annotations": {
            "encourage particpatioin": "Dr. Anna Moore is directly asking Sixian if they are comfortable talking about the topics discussed, encouraging them to participate in the conversation."
        }
    },
    {
        "utterance": "Sixian You: Actually, uh, yeah, I I think I can only catch understand like 50% of these conversations. I think my biology is probably high school level, so. ",
        "annotations": {
            "express humor": "The speaker is making a self-deprecating joke about their limited understanding of the complex biological concepts being discussed, implying their biology knowledge is only at a high school level."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's pretty good though. 50%'s pretty good. ",
        "annotations": {
            "express agreement": "Benjamin Bartelle expresses agreement with the previous speaker's statement that understanding 50% of the conversation is pretty good, showing support for Sixian You."
        }
    },
    {
        "utterance": "Sixian You: So if anybody wants to take over, I'm totally comfortable because I think the best thing is that we present the best ideas in the room. Um, yeah. ",
        "annotations": {
            "encourage particpatioin": "Sixian You is offering to relinquish their note-taking role, encouraging someone else to take over and contribute to summarizing the best ideas from the meeting.",
            "express agreement": "Sixian You expresses agreement with the idea of presenting the best ideas in the room."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Nah, you got this. Come on. ",
        "annotations": {
            "encourage particpatioin": "Benjamin encourages Sixian to continue summarizing the discussion, showing support for Sixian's ability to handle the task."
        }
    },
    {
        "utterance": "Sixian You: Okay. So. ",
        "annotations": {
            "None": "This utterance does not contain any specific content that can be categorized using the provided codes, as it is simply an acknowledgement."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Do we we have our our barriers, our targets, our agents, our approaches. This is all getting really well organized, so I. ",
        "annotations": {
            "express agreement": "Benjamin expresses agreement that the discussion is well-organized, building on the previous summarization of ideas and approaches."
        }
    },
    {
        "utterance": "Sixian You: Oh. ",
        "annotations": [
            {
                "acknowledge contribution": "The speaker is acknowledging the previous conversation, but not agreeing or expanding on it."
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: I think it's really shaping up. ",
        "annotations": {
            "express agreement": "Benjamin Bartelle expresses agreement with the progress of the discussion, building on the previous turn where Sixian You was feeling overwhelmed and Benjamin encouraged them to continue."
        }
    },
    {
        "utterance": "Sixian You: Okay. So, uh, I guess to start, we can kind of present to the room like what are the barriers? Uh, and the barriers of course, disparity between the models and uh, the lack of understanding, uh, and the lack of tools to um, to validate toxicity and efficacy uh, in the short timeline. ",
        "annotations": [
            {
                "explain or define term or concept": "Sixian is defining the topic of discussion as the barriers to translating models to humans, setting the stage for the group to brainstorm and present these challenges."
            },
            {
                "present new idea": "Sixian is presenting the idea of discussing the barriers to translation, which is a new direction for the conversation at this point."
            }
        ]
    },
    {
        "utterance": "Sixian You: And then to address that, we could first we could um, focus more efforts on different targets, uh, list at this and then contrast agency is another effort and then uh, in the end it will be a combination multi model approaches of all this. ",
        "annotations": {
            "propose decision": {
                "Explanation": "The speaker is suggesting a concrete choice for the group to focus more efforts on different targets and contrast agents to address the barriers discussed."
            },
            "expand on existing idea": {
                "Explanation": "The speaker is building on the previous discussion about barriers and suggesting specific approaches to address them, such as focusing on different targets and contrast agents, and ultimately using a combination of multimodal approaches."
            }
        }
    },
    {
        "utterance": "Sixian You: Where does imaging come in? The multimodal approaches in the contrast agents? ",
        "annotations": {
            "ask clarifying question": "Sixian is asking where imaging fits into the multimodal approaches and contrast agents that have been discussed, seeking clarification on its role."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. I mean that's what we mean by multimodal, multimodal imaging. ",
        "annotations": {
            "explain or define term or concept": "Benjamin is explaining what is meant by 'multimodal' in the context of the discussion, clarifying that it refers to multimodal imaging."
        }
    },
    {
        "utterance": "Crystal Rogers: Well, and also in the technological development, right, to be able to actually see the efficacy of these things live in an organism. Someday. ",
        "annotations": [
            {
                "expand on existing idea": "Crystal is building upon the previous discussion about multimodal approaches and contrast agents, adding that technological development is also needed to see the efficacy of treatments live in an organism."
            },
            {
                "express enthusiasm": "Crystal expresses optimism about future technological development by saying \"Someday.\""
            }
        ]
    },
    {
        "utterance": "Benjamin Bartelle: Is is is multimodal approaches a subset of technological development then? ",
        "annotations": {
            "ask clarifying question": "Benjamin is asking a clarifying question about whether multimodal approaches are a subset of technological development, seeking to understand the relationship between the two concepts."
        }
    },
    {
        "utterance": "Crystal Rogers: It is. Yes. ",
        "annotations": {
            "express agreement": "Crystal Rogers explicitly agrees with Benjamin Bartelle's question about whether multimodal approaches are a subset of technological development, confirming his statement."
        }
    },
    {
        "utterance": "Sixian You: Yeah. Uh-huh. ",
        "annotations": {
            "express agreement": "Sixian You is agreeing with Crystal Rogers' statement that multimodal approaches are a subset of technological development, building on the discussion about barriers, targets, agents, and approaches."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I guess all this stuff then. These things are all like uh development of 3D culture, visualization of delivery. That's all tech development that we're all tracking. ",
        "annotations": {
            "expand on existing idea": "Benjamin is summarizing the discussion, building on the previous points about multimodal approaches and technological development by listing examples like 3D culture and visualization of delivery, which are all part of tech development."
        }
    },
    {
        "utterance": "Sixian You: So, I can delete this and uh, put multimodal approaches here. ",
        "annotations": {
            "propose decision": "Sixian is suggesting a concrete change to the slide, proposing to replace the current content with 'multimodal approaches'."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. ",
        "annotations": [
            {
                "express agreement": "Benjamin is agreeing with Dr. Anna Moore, who just said that Ben did an amazing job the last time."
            }
        ]
    },
    {
        "utterance": "Crystal Rogers: I think the 3D cell culture stuff is also part of technological development, bioprinting, etc. ",
        "annotations": {
            "expand on existing idea": "Crystal is building on the previous discussion about technological development and imaging, adding that 3D cell culture and bioprinting are also part of technological development."
        }
    },
    {
        "utterance": "Sixian You: Uh, that is also, okay. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "Sixian acknowledges the previous statement about 3D cell culture being part of technological development, indicating understanding and agreement."
            }
        }
    },
    {
        "utterance": "Sixian You: I think we talked about this before. Yeah, particle, nanoparticle is already in the contrast agents. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "Sixian acknowledges that the point about nanoparticles has already been discussed, recognizing a prior contribution to the conversation."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: You can make the the font smaller too if it doesn't fit. That's uh that's the easy one. ",
        "annotations": {
            "express humor": "Benjamin is making a lighthearted suggestion about adjusting the font size, implying it's a simple solution to a potential formatting issue on the slide, which expresses humor."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: I also want to add the concept of like live contrast agents, like what happens with magnetotactic bacteria because like the dilution of the like the contrast agent is a big problem in the like the cell proliferation. ",
        "annotations": {
            "expand on existing idea": "Morteza is expanding on the discussion about contrast agents by introducing the concept of live contrast agents, building on the previous discussion about the challenges of contrast agent dilution during cell proliferation."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. ",
        "annotations": {
            "expand on existing idea": "Benjamin is building on the idea of live contrast agents that Morteza brought up, explaining that genetic reporters inherently function as live contrast agents because they persist and replicate within cells."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: So the live contrast like there are papers coming out showing basically that magnetotactic bacteria can be used for like even increasing the like uh imaging uh sensitivity and capacity at the side of like for cell therapy applications, they they at least they showed promising results. So maybe adding. ",
        "annotations": {
            "expand on existing idea": "Morteza is expanding on the idea of contrast agents by suggesting the use of magnetotactic bacteria to increase imaging sensitivity, building on the previous discussion about the limitations of current contrast agents and the need for better imaging techniques for cell therapy applications."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. It's a a live reporter. I mean, I I agree. I agree with you completely. ",
        "annotations": {
            "expand on existing idea": "Benjamin is expanding on Morteza's idea of live contrast agents by linking it to the concept of genetic reporters, suggesting that genetic reporters inherently function as live contrast agents.",
            "express agreement": "Benjamin explicitly agrees with Morteza's point about live contrast agents, reinforcing the connection between genetic reporters and live imaging."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, we have uh probably one or a little bit over one minute left. So I just wanted to say that uh I I think it was fun. I think you know, I think we discussed a lot of different questions because the topic is so broad. And um if you guys you know, if you guys want to talk more about it, you know, my email is there. Uh you can email me or you can email each other. Please, um and uh hopefully we'll get this going and uh I'm looking forward to forming proposals from you guys. Just think what what you want to do. Um, you have complimentary expertise. Um, so we have a clinical person here. That's unique. So grab his expertise before it's too late. ",
        "annotations": [
            {
                "express enthusiasm": "Dr. Anna Moore expresses that she thinks the discussion was fun, indicating enthusiasm for the meeting."
            },
            {
                "encourage particpatioin": "Dr. Anna Moore encourages further discussion and collaboration by providing her email and suggesting participants email each other."
            },
            {
                "acknowledge contribution": "Dr. Anna Moore acknowledges the unique expertise of the clinical person in the group."
            }
        ]
    },
    {
        "utterance": "Lisa Poulikakos: Thanks everyone. I feel like I learned a lot as a physics engineering person and I really appreciated the discussion. ",
        "annotations": {
            "express enthusiasm": "Lisa expresses her appreciation for the discussion and acknowledges that she learned a lot, indicating enthusiasm for the conversation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Good. ",
        "annotations": [
            {
                "express enthusiasm": "Dr. Anna Moore ends the session with a positive affirmation, indicating satisfaction with the discussion."
            }
        ]
    },
    {
        "utterance": "Dr. Anna Moore: Me too. ",
        "annotations": [
            {
                "express agreement": "Dr. Anna Moore is expressing agreement with Lisa Poulikakos who said she learned a lot from the discussion."
            }
        ]
    },
    {
        "utterance": "Sixian You: Yeah, I learned all the all the dark size and potentially price size of therapy. What I learned again is biology is so hard and medicine is so hard. ",
        "annotations": [
            {
                "express humor": "The speaker is making a lighthearted comment about the challenges of therapy, biology, and medicine, expressing a humorous take on the difficulties discussed."
            }
        ]
    },
    {
        "utterance": "Lisa Poulikakos: I really really liked what Crystal said about the communication being key as we do push forward with anything shiny and new. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "Lisa acknowledges Crystal's point about the importance of communication, showing recognition of her contribution to the discussion."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I totally agree. ",
        "annotations": {
            "express agreement": "Dr. Anna Moore is explicitly agreeing with Lisa Poulikakos's statement about the importance of communication as new technologies are developed."
        }
    },
    {
        "utterance": "Dylan Burnette: And I liked what Molly said about the difficulty with integrating over time scales and and having tractable metrics for many of the different diseases. ",
        "annotations": {
            "acknowledge contribution": {
                "Explanation": "Dylan acknowledges Molly's point about the difficulty with integrating over time scales and having tractable metrics for different diseases, recognizing her contribution to the discussion."
            }
        }
    }
]